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ABSTRACT 
 
SNAMA is a 139 kDa Drosophila melanogaster protein belonging to the 
Retinoblastoma Binding Protein 6 (RbBP6) superfamily. Mammalian 
RbBP6 interacts with both p53 and Rb and plays a critical role in 
embryonic development and tumorigenesis as a negative regulator of p53. 
All RbBP6 members contain a 5´ DWNN Catalytic Domain (DCM) 
consisting of a DWNN (domain with no name) domain followed by a zinc 
finger and RING (really interesting new gene) finger motif. RING finger 
and U-box ubiquitin ligases are dependent on their RING finger 
conformation for their ubiquitin ligase activity. The main focus of this work 
was to further elucidate the functional characteristics of the DCM within 
SNAMA. This was achieved by examinining transcription regulation of the 
SNAMA gene and determining whether SNAMA exhibits ubiquitin ligase 
activity. 5´ Rapid amplification of cDNA ends (RACE) was used to 
determine the core promoter elements of SNAMA through the discovery of 
the transcription initiation site. Ubiquitin conjugation assays using pure 
recombinant SNAMA as the ubiquitin ligase were performed to analyze the 
ubiquitin ligase activity of the protein. Transcriptional regulation of the 
SNAMA gene is achieved through a single TATA-less promoter that gives 
rise to a single transcript of 3.9 kb. Furthermore, this work shows that 
SNAMA is a unique RING finger ubiquitin ligase that is capable of auto-
ubiquitination in the absence of zinc ions. This activity is dependent on its  
RING finger-like motif, which has greatest specificity to the UbcH5a 
conjugating enzyme. Furthermore, SNAMA relies on E1, E2, ATP, and 
ubiquitin for its E3 activity. Thus, SNAMA is the first member of the 
RbBP6 family to portray RING finger ubiquitin ligase activity and 
represents a “drugable” target for pharmaceutical intervention.  
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1. INTRODUCTION 
 
1.1 Drosophila melanogaster as a Model Organism 
 
Drosophila melanogaster (meaning dark-gut dew-lover) is a common fruit fly 
belonging to the family Drosophilidae and found in the order Diptera. It is 
therefore classified as an insect. It was first used as a model organism in the 
early 1900’s by Nobel Prize winner Thomas Hunt Morgan for his genetic 
research on sex-linkage and genetic recombination (Morgan et al., 1915).  
 
Drosophila is a very popular and successful model organism due to the great 
number of properties that it possesses. It has a short generation time of 10-12 
days making it possible to study numerous generations in an academic year 
(Kramer, 1986; Sofer and Tompkins, 1994). It is easily cultured and inexpensive 
to house in large numbers (Jeszenszky, 1997; Kramer, 1986). Due to its small 
size Drosophila is suitable for cultivation in laboratories yet it is large enough 
for many attributes to be seen with the naked eye or under low-power 
magnification (Sofer and Tompkins, 1994). It has a high rate of reproduction 
with a female laying hundreds of fertilized eggs during her brief life span. Giant 
polytene chromosomes that show far more structural detail than do normal 
chromosomes are found in the salivary and other glands of the mature larvae 
(Mortin and Sedat, 1982). Furthermore, the Drosophila embryo grows outside 
the body and can be easily studied at every stage of development. 
 
Since Thomas Hunt Morgan, for over a century Drosophila has been used as a 
popular model organism in heredity and biomedical research where the aims are 
to understand human genetics and developmental processes (Celniker, 2000). 
This is possible due to Drosophila showing the same developmental plasticity as 
that seen in humans but having less redundancy, allowing for easier dissection of 
function (Richardson and Kumar, 2002). More recently Drosophila has been 
used for what it does best: identifying novel oncogenes and tumor suppressors, 
and linking cancer-related genes together into complex signalling pathways 
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(Vidal and Cagan, 2006). This was facilitated by the completion of the 
Drosophila euchromatic genomic sequence (Celniker, 2000), which revealed 
that two thirds of genes involved in human cancers have counterparts in 
Drosophila (Vernooy et al., 2000).  
 
Perhaps the greatest advantage of Drosophila is its powerful genetics. This can 
be used to generate mutations and transgenic lines that ectopically overexpress 
genes, examine genetic interactions, and carry out dominant genetic modifier 
screens to uncover novel genes (Richardson and Kumar, 2002). All of these 
genetic approaches have been used for comparative study of programmed cell 
death between Drosophila and humans.   
 
1.2 Programmed Cell Death Within Drosophila melanogaster 
 
Regulation of programmed cell death or apoptosis is a delicately controlled 
process, one which is critical to a wide variety of developmental processes. This 
includes removal of unnecessary anatomical structures, control of cell number, 
morphological sculpting, and elimination of injured or dangerous cells (Jacobson 
et al., 1997). Regulation of cell number is critical for proper organism 
development and homeostasis. In Drosophila, programmed cell death can be 
controlled intrinsically through caspase-dependent pathways such as the Grim 
Reaper or Hippo pathways (Figure 1). The intrinsic cell death system is 
controlled predominantly by: pro-apoptotic activators (H99 genes), caspases, 
inhibitor of apoptosis proteins (IAP), and tumour suppressors. Alternatively, an 
extrinsic cell death-inducing mechanism is used whereby the physiological 
ligand Eiger stimulates cell death via the JNK pathway (Igaki et al., 2002). 
 
1.2.1 Pro-apoptotic activator genes 
 
Only five pro-apoptotic activators have been discovered in Drosophila thus far, 
they are reaper (rpr), grim, head involution defective (hid), sickle (skl), and 
jafrac2 (Cashio et al., 2005). Rpr, grim and hid are three closely linked genes 
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contained within the H99 cell death locus (Chen et al., 1996), while skl is found 
just outside the H99 locus (Srinivasula et al., 2002; Wing et al., 2002). In 
contrast, jafrac2 is found in a very different position of the genome that still 
contains H99-like characteristics (Tenev et al., 2002). The domain structure of 
these pro-apoptotic genes and the functional human homologue, Smac, share a 
conserved N-terminal region known as the RHG (Reaper Hid Grim) motif 
(Wing et al., 2001). Outside this motif they are not similar and vary significantly 
in size. The RHG motif has been shown to competitively bind a domain in the 
IAP family and in so doing prevents inhibition of caspase activity. It is thus clear 
that the RHG motif is important in the pro-apoptotic function of the activator 
proteins. 
 
Rpr expression is regulated by the steroid hormone ecdysone and by 
developmental signals (Jiang et al., 2000; Nordstrom et al., 1996). Grim, like 
Rpr, is also expressed in cells destined for death whereas Hid has a more general 
expression pattern (Chen et al., 1996). Hid is negatively regulated at both 
transcriptional and posttranscriptional levels by the epidermal growth factor 
receptor (EGFR)-Ras-Raf-MAPK signaling pathway (Grether et al., 1995; 
Bergmann et al., 1998; Kurada and White, 1998). Additional in vivo analysis of 
these H99 pro-apoptotic genes is needed in order to determine the factors that 
control its expression.      
 
1.2.2 Caspases 
 
Caspases are commonly implemented during the process of apoptosis. These 
caspases are highly conserved cysteine proteases that specifically target and 
cleave substrates after an aspartate residue (Cashio et al., 2005). Caspases are 
expressed as inactive zymogen precursors that consist of a variable length 
prodomain followed by a large (p20) and small (p10) unit, which are responsible 
for substrate recognition and catalysis. Activation occurs through the 
incorporation of the caspase into large protein complexes, or through the 
separation of the p10 and p20 subunits and reassembly into an active 
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heterotetramer. Once activated, they literally break down the protein scaffolding 
holding the cell together leading to the destruction of the cell and ultimate death 
(Degterev et al., 2003).  
 
Caspases are divided into two general classes: apical caspases (Class I) and 
effector caspases (Class II). Caspases are activated in an amplifying proteolytic 
cascade with cleavage of one another in sequence (Cashio et al., 2005). It 
therefore makes sense that the apical caspases are activated early at the onset of 
apoptosis while downstream effector caspases are activated later by already 
active apical caspases via proteolytic processing. Apical caspases are usually 
characterized according to their long N-terminal prodomain, which contain 
protein-protein binding motifs that are essential for their caspase activity 
(Degterev et al., 2003).            
 
Thus far seven caspase-encoding genes have been identified in the Drosophila 
genome: dcp-1, dredd, drice, dronc, decay, strica, and damm (Kumar and 
Doumanis, 2000; Salvesen and Abrams, 2004).  Based on the prodomain 
structure, Dcp-1, Drice, Decay, and Damm are effector caspases whilst Dronc 
(Drosophila Nedd-2 like Caspase) and Dredd (death related CED-3/Nedd2-like 
protein) are classified as apical caspases. Dronc contains a CARD (Caspase 
Activation and Recruitment Domain) motif in its prodmain and is most similar 
to caspase-2 and -9 in mammals (Dorstyn et al., 1999). Dredd contains a pair of 
DEDs (death effector domain), and although it similar to mammalian caspase-8, 
Dredd doesn’t seem to play a role in the apoptotic immune response (Leulier et 
al., 2000). Strica contains a long prodomain but does not contain any known 
protein-protein interaction motifs, nor are there any mutants for strica that could 
be used to clarify its function (Doumanis et al., 2001). Thus, with the role of 
Strica still unclear it seems as though Dronc is the only “classical” apical 
caspase. Furthermore, various studies have been done that establish Dronc as an 
essential caspase in Drosophila apoptosis (Meier et al., 2000; Quinn et al., 2000; 
Muro et al., 2002).          
 
 17 
1.2.3 Inhibitor of apoptosis proteins (IAPs) 
 
The key role of IAPs in both mammals and Drosophila is to bind to caspases 
thereby rendering them biochemically inactive and ultimately preventing 
apoptosis from taking place (Salvesen and Duckett, 2002). IAPs are highly 
conserved throughout all eukaryotes and share several structural motifs (Miller, 
1999). An example is the presence of between one and three tandem baculoviral 
IAP repeat (BIR) motifs, which is indicative of an IAP family member (Salvesen 
and Duckett, 2002). The BIR motif is essentially a Zn-binding fold of 
approximately 80 residues that is pivotal for the anti-apoptotic function of IAPs. 
In addition, some IAPs contain a RING (Really Interesting New Gene) finger 
domain that confers E3 ubiquitin ligase activity, leading to ubiquitin-mediated 
protein degradation. Targets for ubiquitination include the caspases, the H99 
proteins and the IAPs themselves. IAPs appear to interact with only a certain 
subset of caspases and it does so through the BIR motifs. Those with more than 
one BIR motif fold into functionally independent structures, each with different 
substrate specificity (Cashio et al., 2005). This has been illustrated in Drosophila 
where the BIR1 motif of Drosophila IAP1 (DIAP1) specifically inhibits Dcp-1 
and Drice, whereas BIR2 inhibits Dronc (Zachariou et al., 2003; Chai et al., 
2003; Yan et al., 2004). 
 
There are four IAPs encoded by the Drosophila genome: diap1, diap2, deterin 
and dBruce. Of these the diap1 gene appears to be most important and thus most 
extensively studied. This gene encodes for an IAP with two BIR motifs and a 
single RING domain (Hay et al., 1995). Loss of diap1 results in uncontrolled 
caspase activation causing massive and widespread apoptosis that ultimately 
leads to embryonic lethality (Wang et al., 1999).   
 
1.2.4 The Grim Reaper pathway  
 
The most popular and extensively studied cell death system in Drosophila is that 
involving the activation of the pro-apoptotic genes in the Grim Reaper pathway. 
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In Drosophila cells that have not received apoptotic stimuli, the BIR2 domain of 
DIAP1 binds to the prodomain of Dronc, thus preventing the association of 
Dronc with the human Apaf-1 homologue Dark (Zachariou et al., 2003) (Figure 
1). This DIAP1-Dronc complex allows the RING domain of DIAP1 to catalyze 
the ubiquitination and subsequent degradation of Dronc thereby inactivating it. 
Dronc therefore requires inhibition of complex formation with DIAP1 in order 
to become active. Upon apoptotic stimulation pro-apoptotic H99 proteins (Rpr, 
Grim, Hid, Skl, Jafrac2), through their highly conserved RHG motif, bind with 
high affinity to the BIR2 domain of DIAP1 (Cashio et al., 2005). This prevents 
DIAP1 from forming a complex with the apical caspase Dronc.  
 
In this way H99 proteins function as IAP antagonists. However, it is unclear 
whether this competition leads to displacement of Dronc from DIAP1 or 
whether there is inactivation of free DIAP1 upon H99 protein binding. In either 
case Dronc is free to bind with the adaptor protein Dark and gain activity thus 
becoming “the executioner” of the cell suicide program through the specific 
cleavage of target proteins (Cashio et al., 2005). Meanwhile, DIAP1 undergoes 
degradation through self-ubiquitination (Cashio et al., 2005) and is thought to 
degrade the bound H99 proteins in the same way (Olson et al., 2003). 
 
1.2.5 The Hippo pathway 
 
The Hippo pathway is a recently discovered cell signaling event that 
coordinately controls cell proliferation and apoptosis in Drosophila (Edgar, 
2006). It consists of six pro-apotoptotic components: Merlin, Expanded, Hippo 
(Hpo), Salvador (Sav), Warts/Lats (Wts), and Mob1 as a tumour suppressor 
(Mats), as well as a single anti-apoptotic component: Yorkie (Yki) (Thompson 
and Cohen, 2007). Merlin and Expanded are related FERM-domain proteins that 
are located at the cytoskeleton and are the most upstream components of the 
pathway. Hpo is a MST-family kinase that functions with the adaptor protein 
Sav to either: phosphorylate and decrease stability of DIAP1, or phosphorylate 
and activate Wts. Wts is a NDR-family kinase that functions with the adaptor 
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protein Mats to phosphorylate and inactivate Yki (Colombani et al., 2006). Yki 
is a transcriptional cofactor that functions in promoting cell cycle regulation 
through Cyclin E transactivation and inhibiting apoptosis through expression of 
DIAP1 (Huang et al., 2005). In addition, Yki also activates Merlin and 
Expanded as part of a negative feedback loop (Hamaratoglu et al., 2006). 
Activation of the Hippo pathway in response to irradiation leads to the activation 
of the apical caspase Dronc, and ultimately cell death through proteolytic 
processing. Furthermore, all the components of the Hippo pathway are 
conserved in humans and several have been implicated in human cancer.         
    
 
Figure 1. Programmed cell death in Drosophila melanogaster. Apoptosis is 
controlled intrinsically through caspase-dependent pathways such as the Grim 
Reaper or Hippo pathways. The intrinsic cell death system is controlled by pro-
apoptotic activators (H99 genes), caspases, IAPs, and tumour suppressors. 
Alternatively, apoptosis can occur extrinsically through Eiger via the JNK 
pathway. Dmp53 has a pivotal role in Drosophila melanogaster programmed 
cell death and is linked to both the extrinsic and intrinsic cell death systems.  
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1.2.6 The JNK pathway 
 
A search for cell death-inducing factors, responsible for reduced eye size in 
Drosophila, led to the discovery of the first invertebrate tumour necrosis factor 
(TNF) ligand, Eiger (Igaki et al., 2002). Overexpression of Eiger results in 
severe developmental defects that are distinct from that of Reaper. Eiger induces 
IAP-sensitive cell death through activation of the Drosophila JNK pathway and 
does not require caspase activity (Igaki et al., 2002). Furthermore, the structure 
and function of Eiger suggests that this extrinsic cell death-inducing mechanism 
may be evolutionarily conserved in Drosophila. Eiger binds an Eiger receptor 
containing a TNF receptor homology domain and a transmembrane domain. 
This results in the activation of downstream Misshapen (Msn), a Drosophila 
MAPKKKK, which in turn activates dTAK1, a Drosophila JNKKK. dTAK1 
then activates the Drosophila JNKK, Hemipterous (Hep), which ultimately 
activates the JNK, Basket (Bsk). Bsk is responsible for inducing cell death, 
possibly through JNK-mediated release of mitochondrial caspase-independent 
cell death factors (Igaki et al., 2002). Recent analysis has shown that while 
overexpression of Eiger is sufficient to induce apoptosis, it is not required for 
ionizing radiation (IR)-induced apoptosis (Brodsky et al., 2004). 
 
1.3 Drosophila melanogaster p53 (Dmp53) 
 
1.3.1 Identification of Dmp53 
 
Dmp53 was identified by three groups while performing homology searches in 
Drosophila using the human homologue p53 (Ollmann et al., 2000; Brodsky et 
al., 2000; Jin et al., 2000). It was initially described as a 42 kDa Drosophila 
melanogaster protein of 385 amino acids. Year’s later, after the discovery of a 
conserved internal promoter in mammalian p53, experiments were performed to 
identify an internal promoter in Drosophila p53 (Bourdon et al., 2005).  In so 
doing it was discovered that in fact the Dmp53 gene encodes for three Dmp53 
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isoforms in vitro: dp53L (495 amino acids), dp53 (385 amino acids), and dp53n 
(123 amino acids) (Figure 2). 
 
 
Figure 2. Drosophila melanogaster p53 isoforms: dp53L, dp53, and dp53n. 
dp53 is a N-terminally truncated isoform of an internal promoter and is identical 
to that first published. dp53L is initiated at exon A, 580 bp upstream of the 
internal promoter, and contains the conserved N-terminal domain FxxψW. This 
domain is not found within dp53 and is required to activate gene transcription. 
The third isoform, dp53n, is a splice variant of dp53L with no slicing of intron B 
(Bourdon et al., 2005). 
 
dp53 is initiated at exon 1 and is identical to that first published. In contrast, 
dp53L contains two extra exons (exons A and B) and is initiated 580 bp 
upstream of exon 1. dp53n is a splice variant of dp53L where there is no slicing 
of intron B. Because expression of dp53L is initiated at exon A it contains a 
longer N-terminal domain whereas dp53 is a N-terminally truncated isoform 
produced from an internal promoter (Bourdon et al., 2005). This confirms the 
hypothesis made by Bourdon and his colleagues of a conserved internal 
promoter existing within Drosophila p53, and strongly suggests an essential role 
in the control of p53 family activities. 
 
Alignment of p53 proteins from various families revealed that the only domain 
conserved through evolution within the N-terminal end is the sequence FxxψW 
(Bourdon et al., 2005). It is this domain that is required to activate gene 
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transcription. The dp53L isoform but not the dp53 isoform contains the domain 
FxxψW, indicating that dp53L is homologous to full length p53 and p53-related 
proteins and strongly suggests that dp53L is able to transactivate genes.  
  
Although the overall homology between Dmp53 and human p53 is found to be 
very low, significant similarity has been shown in the central DNA-binding 
domain (Brodsky et al., 2000). This includes residues identified in human p53 
that are critical for DNA sequence recognition and coordination of a zinc ion. In 
contrast, the C- and N-termini of Dmp53 show little similarity with human p53 
(Sutcliffe et al., 2003). Dmp53 does, however, contain secondary structures and 
enriched basic residues at its C terminus and a high proportion of acidic residues 
at its N terminus. These residues at the C- and N-termini of Dmp53 are shared in 
human p53 where they regulate sequence-specific DNA binding and function in 
transcriptional activation respectively (Sutcliffe and Brehm, 2004). Furthermore, 
like human p53 the dp53L isoform contains the highly conserved FxxψW at its 
N-terminus, which is thought to activate gene transcription.   
 
1.3.2 Dmp53 activity 
 
The effect of a dominant-negative Dmp53 on radiation-induced arrest of cell 
cycle progression shows that entry into mitosis is not affected by this mutation 
(Brodsky et al., 2000). More specifically Dmp53 does not engage checkpoint 
controls through the cell cycle such as its human counterpart p53, which 
mediates G1 cell cycle arrest through induction of p21 (Ollmann et al., 2000). 
This is consistent with the observation that the Drosophila p21/p27 homolog, 
dacapo, is not induced by IR (Brodsky et al., 2004). Null mutations in Dmp53 
do not show dramatic effects with flies being viable and semi-sterile (Lee et al., 
2003). However, upon exposure to a DNA damaging stimulus such as radiation, 
Dmp53 is required for apoptosis in the wing (Brodsky et al., 2000). 
Overexpression of Dmp53 is also sufficient to induce apoptosis, but the response 
is either qualitatively or quantitatively different from the apoptotic response to 
DNA damage (Brodsky et al., 2000). Thus, the role of Dmp53 in apoptosis 
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induction has been shown to be conserved. Recently, a genome-wide analysis 
involving IR-induction showed that Dmp53 is not only involved in apoptotic 
regulation but also other cellular pathways that include cell-cell signaling and 
DNA repair (Brodsky et al., 2004).    
 
1.3.3 Regulation of Dmp53  
 
 
Not much is known about the regulation of Dmp53 but the information 
accumulated thus far suggests that Dmp53 is regulated in a partially conserved, 
ancestral way. Upstream regulators of Dmp53 activation include Mei-41 and 
MNK (maternal nuclear kinase), the Drosophila homologs of mammalian ATM 
(ataxia-telangiectasia-mutated) and Chk2 (checkpoint-homologs 2) respectively. 
Both these kinases are involved in DNA damage responses (Brodsky et al., 
2000), with MNK shown to directly activate Dmp53 (Peters et al., 2002).  
 
MNK/dChk2 is required for both induction of cell cycle arrest and apoptosis in 
response to DNA damage (Xu et al., 2001). Furthermore, overexpression of 
Dmp53 results in apoptosis that is enhanced by the co-expression of MNK, but 
not the kinase-inactive form of MNK (Peters et al., 2002).  This effect is 
specific, with no change in apoptotic levels when Dmp53 is co-expressed with 
wild-type and mutant Drosophila Chk1, Grape (Sutcliffe et al., 2003; Brodsky et 
al., 2004). Like its human counterpart, Dmp53 is phosphorylated by MNK 
indicating that posttranslational modification is necessary for Dmp53 activation 
and consequent induction of apoptosis (Brodsky et al., 2004). However, unlike 
its human counterpart, Dmp53 levels remain constant following activation 
(Sutcliffe et al., 2003).  
 
1.3.4 DNA damage-induced targets of Dmp53 
 
Analysis of Dmp53 targets in response to IR identified far less genes in 
Drosophila than p53 gene targets in mammals (Brodsky et al., 2004). Targets of 
mammalian p53 have been identified in many different cell types following 
different sources of DNA damage or simply overexpression of p53. It is 
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therefore likely that additional targets of Dmp53 will be identified when using 
different causes of cellular stresses in different cell types or developmental 
stages. 
 
Dmp53 regulated apoptosis: Intrinsic mechanism 
 
The most prominent group of Dmp53 targets discovered thus far are the pro-
apoptotic genes of the Grim Reaper pathway. Initially, reaper was found to be 
the only effector of the pro-apoptotic function of Dmp53 (Brodsky et al., 2000). 
More recently it has been shown that activated Dmp53 induces programmed cell 
death by expressing additional proapoptotic genes including Hid and sickle 
(Brodsky et al., 2004). Dmp53 transactivates expression of these proapototic 
genes, which leads to the activation of apical caspases through the inhibition of 
IAPs (Wang et al., 1999). In this way caspase activity is increased illustrating 
one way in which Dmp53 induces apoptosis in Drosophila (Brodsky et al. 
2000). Alternatively, activation of apical caspases is accomplished by the 
activation of Dark, the human Apaf-1 homolog, which is activated by the reaper 
protein (Nordstrom and Abrams, 2000). 
 
Although the pro-apoptotic genes reaper, hid, and sickle are Dmp53 
transcriptional targets, removal of these three proteins through chromosomal 
deficiencies only partially suppresses the cell-death effects of IR in embryos 
(White et al., 1994). This implies that there are additional death signals that are 
independent of the Grim Reaper pathway. Recently it has been shown that it is 
possible for the Hippo apoptotic pathway to be activated by IR in a Dmp53-
dependent manner (Colombani et al., 2006). Hpo is required, although not 
entirely, for the cell death response to DNA damage or Dmp53 ectopic 
expression. 
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Dmp53 regulated apoptosis: Extrinsic mechanism 
 
It has recently been shown that the Drosophila TNF homolog, Eiger, is 
transactivated by Dmp53 during IR induction (Brodsky et al., 2004). As 
mentioned earlier, overexpression of Eiger leads to apoptosis through the 
activation of the Drosophila JNK pathway, however, it is not required for IR-
induced apoptosis (Igaki et al., 2002; Brodsky et al., 2004). Thus, it is still 
unclear how transcriptional activation of Eiger by Dmp53, and apoptosis, are 
related following IR induction. It is possible that the conserved activation of the 
JNK pathway by Dmp53 is required for the induction of apoptosis under specific 
conditions that have not been tested for yet. In this way, Dmp53 is thought to be 
involved in cell-cell signaling that ultimately leads to apoptosis in response to 
DNA damage.  
 
1.4 Mammalian p53  
 
 
Human p53 consists of a N-terminal transactivation domain, a central sequence-
specific DNA binding domain, and a C-terminal oligomerization domain 
(Sutcliffe and Brehm, 2004). p53 is a tumor suppressor protein that is 
characterized primarily as a sequence-specific transcription factor (Lee et al., 
2003). In normal unstressed cells, p53 is an inactive short-lived protein, which is 
maintained at very low, almost undetectable levels in the cell. Cellular stresses, 
such as DNA damage, hypoxia, or abnormal oncogene activation, activate and 
increase p53 levels, which lead to inhibition of growth through activities that 
reversibly arrest the cell cycle or promote apoptosis (Vousden, 2000). Activation 
of p53 occurs as a result of post-translational modifications that include 
acetylation and phosophorylation (Oren, 2003). Mutations in p53 are responsible 
for more than half of all human cancers (Levine, 1997; Ryan et al., 2001).  
 
p53-specific E3 ligases such as Mdm2 play a pivotal role in regulating p53 
levels in cells under normal conditions. Mdm2 is involved in an autoregulatory 
negative feedback loop with p53, whereby p53 induces Mdm2 expression and 
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Mdm2 represses p53 activity (Wu et al., 1993). This serves as a vital mechanism 
for restraining p53 function in normal cells without stress (Midgley and Lane, 
1997; Michael and Oren, 2002).  The N-terminal region of Mdm2 binds p53 to 
form a tight complex that controls p53 function either through the physical 
inhibition of p53-mediated transcriptional activity (Chen et al., 1995), or by p53 
degradation (Haupt et al., 1997). The RING finger motif at the N-terminal of 
Mdm2 allows it to function as an E3 ubiquitin ligase that ubiquitinates p53, 
thereby targeting it for degradation by proteasome (Honda et al., 1997) (Figure 
3). Interestingly, in addition to p53, Mdm2 catalyzes ubiquitination of itself 
(Fang et al., 2000).  
 
Recent studies have shown that Mdm2-mediated ubiquitination is not the only 
regulator of p53, although it is the most important. An in vivo mutant of p53, 
that lacks major Mdm2 ubiquitination binding sites, has been shown to contain a 
normal half-life that is stabilized and activated in response to stress (Feng et al., 
2005; Krummel et al., 2005). Furthermore, E3 ligases other than Mdm2 have 
been shown to specifically bind p53 and promote its degradation via 
ubiquitination (Brooks and Gu, 2006). Pirh2, a RING-H2 domain-containing 
protein, interacts with p53 and promotes Mdm2-independent p53 ubiquitination 
and degradation (Leng et al., 2003). Like Mdm2, Pirh2 is a p53 responsive gene 
that participates in a similar autoregulatory negative feedback loop. Another E3 
ligase, COP1, is also a p53-inducible gene that can ubiquitinate and degrade p53 
(Dornan et al., 2004). ARF-BP1, a HECT domain containing E3 ligase, was 
recently identified and is also capable of p53 ubiquitination and degradation 
(Chen et al., 2005). However, the ARF-BP1 ligase lacks a feedback loop that is 
present in the other ligases examined. Together, Mdm2, COP1, Pirh2, and ARF-
BP1 represent an array of E3 ligases that the cell can call upon to regulate and 
maintain p53 levels (Figure 3). This suggests that both Mdm2-dependent and –
independent mechanisms are used cooperatively by the cell for tight p53 
regulation. 
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The genomes of H. sapiens, M. musculus, D. melanogaster, and C. elegans were 
screened for putative homologs of the aforementioned p53-specific E3 ligases 
(Brooks and Gu, 2006) (Table 1). Lower organisms such as C. elegans and D. 
melanogaster, which have fully functional p53, lacked the Mdm2 ortholog. 
Counterparts of the COP1 ligase were also absent in these lower organisms, 
although a homolog for Pirh2 was identified in Drosophila (Yi and Deng, 2005; 
Bernards and Hariharan, 2001). The ARF-BP1 gene is well conserved in all 
organisms.        
 
Table 1. Ubiquitin ligases specific for p53 ubquitination and degradation. 
Genomes of H. sapiens, M. musculus, D. melanogaster, and C. elegans were 
screened for putative homologs to a number of E3 ligases that included Pirh2, 
COP1, Mdm2, and ARF-BP1 (Brooks and Gu, 2006).  
 H. Sapiens M. Musculus D. melanogaster C. elegans Type 
Pirh2 + + + - RING 
COP1 + + - - RING 
Mdm2 + + - - RING 
ARF-
BP1 
+ + + + HECT 
 
DNA damage activates p53 through post-transcriptional modifications that 
include acetylation and phosophorylation (Oren, 2003). Acetylation of residues 
at the C-terminus of p53 during times of cell stress serves to block protein 
degradation by ubiquitination and stabilize p53 (Brooks and Gu, 2006). In 
addition Mdm2 can be acetylated at residues in its RING finger domain thereby 
inactivating the protein and increasing p53 transcriptional activity. Mdm2 can 
only bind to dephosphorylated p53, therefore under stressful conditions when 
there is a need for increased p53 activity, Mdm2 binding is prevented by p53 
phosphorylation (Figure 3). Hence, the interaction between Mdm2 and p53 is 
disrupted, and Mdm2 can no longer target p53 for ubiquitination. 
 
 28 
 
Figure 3. Regulation of p53 and Mdm2 during cell survival and apoptosis. In 
normal cells under no stress, extremely low levels of p53 are evident due to 
ubiquitination and degradation of p53 by E3 specific ligases such as Mdm2. 
Upon cell stress through DNA damage, p53 becomes stabilized and activated by 
post-translational modifications (Brooks and Gu, 2006).   
 
Direct or indirect phosphorylation of p53 is controlled by DNA damage-induced 
kinases such as ATM, Chk1, and Chk2, which leads to p53 activation (Canman 
et al., 1998; Shieh et al., 2000). Once activated, p53 moves into the nucleus 
where it binds to specific enhancers and regulates transcription of adjacent genes 
(Oren, 2003). p53 target genes include p21, which regulates cell cycle 
progression, RNR2, GADD45, which enhances DNA repair, bax, which has role 
in apoptosis (Miyashita and Reed, 1995), and p53-specific E3 ligases, which act 
in a negative feedback pathway to downregulate p53 activity (Brodsky et al., 
2004). At least ten p53 target genes encode potential proapoptotic proteins that 
include regulators of the intrinsic apoptotic mechanism, such as Apaf1, HTRA2, 
and BH3-containing proteins, as well as members of the TNF receptor family 
that regulate the extrinsic apoptotic mechanism (Brodsky et al., 2004). Why so 
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many proapoptotic genes are regulated by p53 and the relative contributions of 
these genes to damage-induced apoptosis is unclear. 
 
A better understanding of p53-regulated pathways could lead to improved 
strategies for treating p53-deficient tumors. However, the apparent complexity 
of p53 function in vertebrates has hampered efforts to elucidate these pathways 
(Ollmann et al., 2000). Furthermore, the way in which p53 determines the type 
of genes (cell cycle arresting or apoptotic) to activate in these given pathways is 
not well understood (Sutcliffe et al. 2003). Understanding the way in which 
Dmp53 controls apoptosis in the fly, where there is no cell cycle mediation, 
could provide insight and clarity as to how p53 regulates apoptosis and its role in 
the various regulatory pathways in humans. This would aid in the battle to 
prevent tumorogenesis through p53 regulation.    
 
1.5 SNAMA 
 
SNAMA, a Xhosa word referring to something that sticks like glue, is a 1231 
amino acid Drosophila melanogaster protein with a molecular weight of 139 
kDa. It contains a highly conserved N-terminal region, which I refer to as the 
DWNN Catalytic Module (DCM) (Figure 4). The DCM is comprised of an 
ubiquitin-like domain known as DWNN (Domain With No Name), followed by 
a zinc finger motif and a RING finger-like motif  (Mather et al., 2005). At its C-
terminus SNAMA contains two lysine-rich regions.  
 
Figure 4. Schematic representation of the Drosophila SNAMA protein. 
SNAMA contains a highly conserved N-terminal region known as the DWNN 
Catalytic Module (DCM) encompassing a DWNN domain, Zn finger, and RING 
finger-like motif. 
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SNAMA was identified through homology searches using a highly conserved N-
terminal domain known as DWNN (Mather et al., 2005). Orthologues of 
SNAMA include yeast Mpe1, which is involved in 3´  end mRNA processing 
(Vo et al., 2001), as well as RbBP6 (retinoblastoma binding protein 6) and its 
derivatives (Sakai et al., 1995; Simons et al. 1997). These SNAMA orthologues, 
including all members of the RbBP6 protein family studied thus far, contain the 
N-terminal DCM (Figure 5). The DCM is highly conserved throughout all 
eukaryotes but absent in prokaryotes (Pugh et al., 2006). Furthermore, the DCM 
is expressed independently in higher organisms and is therefore likely to have a 
conserved function in protein modification and regulation. 
 
 
Figure 5. The domain structure of the RbBP6 family of proteins. The highly 
conserved DCM of the RbBP6 superfamily is shown by the DWNN domain 
(yellow), zinc finger motif (red) and RING finger motif (blue). Both the DCM 
and DWNN domain are expressed as individual polypeptides. Human RbBP6 
contains additional domains that include the Rb-binding domain (green) and 
p53-binding domain (light blue) (Pugh et al., 2006).    
   
Comparative analysis of SNAMA cDNA and genomic DNA shows that the 
transcriptional unit is made up of nine exons and eight introns (Mather et al., 
2005). All introns are very short with the exception of introns 1 and 6, which are 
0.84 kb and 0.3 kb respectively. An unorthodox translational start site was 
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determined at position 1702 of the genomic sequence (Cavener, 1987), due to no 
other upstream methionine codon being present and there being an upstream, in 
frame stop codon. The transcriptional start site for SNAMA has not been 
determined experimentally. However, it was predicted using the BDGP Neural 
Network Promoter prediction programme (http://www.fruitfly.org/seq_tools/ 
promoter.html), to be approximately 2.2 kb upstream of the translational start 
site.         
 
SNAMA is located at position 60B9 on the right arm of chromosome 2 in the 
Drosophila genome (Flybase). SNAMA is expressed as a 3.9 kb transcript 
throughout development along with an uncharacterized 1.8 kb fragment (Jones et 
al., 2006). Expression levels are extremely low in adult flies and unlike Dmp53 
that is expressed at high levels in females (Jin et al., 2000), SNAMA levels are 
low in both males and females (Mather et al., 2005). SNAMA mutants die 
during embryogenesis when homozygous. In addition, Drosophila mutants with 
a P-element insertion in the first intron, exhibit an early occurrence of ectopic 
apoptosis in the blastoderm (Mather et al., 2005). This pattern was not present in 
wild type embryos or after the P-element was precisely excised. Furthermore, 
reduced levels of SNAMA mRNA is visible during late stages of development 
when normal apoptosis is taking place.        
 
Rb and p53 play a central role in cell cycle regulation and programmed cell 
death. It is believed that that RbBP6 and its derivatives are involved in these 
processes and may affect apoptosis due to their association with Rb and p53. 
SNAMA, like other members of the RbBP6 family of proteins, is believed to 
regulate Dmp53 stability (Du and Dyson, 1999), whereby Dmp53 and/or RBF 
(the Drosophila homologue of Rb) act as the substrates for DWNN in protein-
protein interactions. This is plausible, especially in the absence of Mdm2 or a 
p53-specific ligase in the fly. In addition, preliminary work shows that Dmp53 
binds SNAMA. This suggests that SNAMA is a member of a distinct family of 
proteins that plays a role in Drosophila development and apoptosis, probably as 
a suppressor of apoptosis or negative regulator of an activator of apoptosis. 
 32 
1.5.1 The domain with no name (DWNN) 
 
The DWNN domain was initially identified by Professor Jasper Rees through a 
promoter trap mutagenesis screen for apoptotic genes in CHO (Chinese Hamster 
Ovary) cells (Pugh et al., 2006). It was characterized using the RbBP6 protein as 
a template and described as an ubiquitin-like N-terminal domain of 81 amino 
acid residues (Pugh et al., 2006). Similarly, it was shown that DWNN secondary 
structure in SNAMA has the highest score of similarity with ubiquitin, followed 
closely by ubiquitin-like proteins including Nedd8 and Rub1 (Mather et al., 
2005). Thus, although there is only 18-22% sequence identity between DWNN 
and ubiquitin, the structural fold of DWNN is significantly similar to that of 
ubiquitin. Furthermore, DWNN contains the exposed ubiquitin-like C-terminal 
tail extending beyond the β-sheet. Unlike ubiquitin, however, DWNN lacks the 
smaller 310 α-helix normally found, and is believed to contain an additional short 
piece of anti-parallel β-sheet immediately prior to the α-helix  (Mather et al., 
2005; Pugh et al., 2006). 
 
The G75 and G76 residues found in ubiquitin molecules are required for 
recognition by specific hydrolases, which cleave between the di-glycine 
residues. This initiates the process of conjugation, thus allowing for protein 
modification to occur. These di-glycine residues are absent in the DWNN 
domain of SNAMA and yeast but present at positions 78 and 79 of human and 
mice DWNN (Figure 6). Thus it is believed that the DWNN domains containing 
the di-glycine motif are involved in a similar process of conjugation as ubiquitin, 
which is referred to as DWNNylation (Pugh et al., 2006). A highly conserved 
proline has replaced the G76 in DWNN. When this conserved glycine is replaced 
by a proline, as in DSK2 from yeast, cleavage by deubiquitinating enzymes does 
not occur (Biggins et al., 1996). Thus, it is possible that DWNN domains where 
there is no di-glycine motif present (such as in SNAMA) do not modify other 
proteins, at least in a way that requires cleavage by the known and specific 
hydrolases. Alternatively, DWNN could be cleaved by a different set of 
uncharacterized enzymes. The DWNN domain lacks the conserved equivalents 
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of K48 and K63 that are usually found in ubiquitin, although K6 and K29 are 
highly, although not absolutely, conserved. Both K48 and K29 are required for 
poly-ubiquitin chain formation and targeting modified proteins for 26S 
proteasome degradation (Pugh et al., 2006).   
 
 
Figure 6. Multiple alignment of DWNN from various organisms. Dros-DWNN 
= SNAMA, Dros-Ub = Drosophila ubiquitin, Human-DWNN1 = long human 
homolog, Human-DWNN2 = short human homolog, Yeast-DWNN = S. 
cerevisiae homolog (Mather et al., 2005).   
 
Protein sequence alignment of many different DWNN homologs from 
eukaryotes showed great similarity to each other and no similarity to any other 
sequences within the database, including prokaryotes (Mather et al., 2005; Pugh 
et al., 2006). Thus, it is believed that DWNN is a novel protein motif that 
emerged soon after the emergence of eukaryotes. Furthermore, the DWNN 
domain is independently expressed in higher vertebrates providing further 
evidence that it functions as a novel ubiquitin-like modifier of other proteins 
(Pugh et al., 2006). This is consistent with the discovery of a superfamiliy of 
ubiquitin-like domains in recent years (Schwartz and Hochstrasser, 2003). This 
superfamily is separated into the ubiquitin-like proteins (UBL’s), that contain the 
ubiquitin-like domain only, and ubiquitin domain proteins (UDP’s), that are 
larger proteins containing one or more ubiquitin-like domains. DWNN is the 
first example of a ubiquitin-like domain that is alternatively expressed both as a 
UBL and as a UDP (Pugh et al., 2006).    
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1.5.2 The zinc finger 
 
Zinc fingers can best be described as small protein domains that are structured 
around a zinc ion, which forms part of the domain core and is sequestered from 
the solvent by cysteine and histidine residues (Krishna et al., 2003). The zinc 
finger, CCHC, like that found in SNAMA is known as a “zinc knuckle” (Klein 
et al., 2000; Darlix et al., 1995). This is because it is composed of two short β-
strands connected by a turn (zinc knuckle), followed by a short helix or a loop 
(Krishna et al., 2003). Zinc knuckles have been found in a number of mRNA-
associated proteins that include the splicing factors SLU7, h9G8, and hSF1 
(Lopato et al., 1999). In general, zinc finger motifs tend to promote protein-
protein and protein-DNA interactions (Matthews et al., 2000). This is interesting 
as this could support its “neighbor”, DWNN, which contains an ubiquitin-like 
structure and is thought to be involved in protein interactions.  
 
1.5.3 The RING finger-like domain: C3SC4 
 
The RING finger domain of SNAMA differs from characteristic RING fingers 
due to the substitution of the histidine residue, normally present in the fourth 
ligand, with a serine residue (Mather et al., 2005). Thus, SNAMA contains a 
C3SC4 RING finger-like domain with sequence Cys-X2-Cys-X11-Cys-X1-Ser-
X2-Cys-X2-Cys-X12-Cys-X2-Cys, instead of the classical C3HC4 consensus 
(Figure 7). RING finger ligases are dependent on their RING finger motif for 
activity, as they play an essential role in conjugation of ubiquitin to target 
proteins (Joazeiro and Weissman, 2000). Although SNAMA contains an 
uncharacteristic RING finger motif it is still suspected that the RING finger-like 
domain will function as an ubiquitin ligase. This hypothesis is supported by the 
fact that proteins with uncharacteristic C4C4 RING finger-like domains still 
portrayed ubiquitin ligase activity. This was the case with the transcription-
associated proteins CNOT4 (Albert et al., 2002) and p44 (Fribourg et al., 2000), 
which contain C4C4-type RING fingers. Furthermore, a threonine residue, an 
amino acid with a hydroxyl group in its side chain like serine, replaces Cys3 in 
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the Mdm2 RING finger without affecting the overall structure or its ubiquitin 
ligase activity (Saurin et al., 1996). 
 
 
Figure 7. The “cross-brace” structure of RING finger motifs. (A) The classical 
C3HC4 RING finger, where two zinc ions are co-ordinated by cysteine residues 
(yellow spheres) and a histidine residue (blue sphere). (B) The uncharacteristic 
C3SC4 RING finger-like motif found within the DCM of SNAMA. Two zinc 
ions are co-ordinated by cysteine residues and a serine residue (pink sphere), 
(Mather et al., 2005).  
 
1.6 The Retinoblastoma Binding Protein 6 (RbBP6) Superfamily 
 
RbBP6 is one of the few proteins studied that is shown to interact with both p53 
and Rb (Sakai et al., 1995; Simons et al., 1997). Thus, it is likely that this protein 
plays a role in the induction of apoptosis and regulation of the cell cycle. Three 
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partial cDNA’s from the full length RbBP6 transcript were originally cloned and 
sequenced in different studies. RBQ-1 from humans (Sakai et al., 1995), 
corresponding to residues 150-1146 of the human protein, and PACT (p53-
associated cellular protein-testes derived) from mice (Simons et al., 1997), 
corresponding to residues 207-1792, were cloned on the basis that they bind Rb 
and p53. P2P-R (proliferation potential protein-related), corresponding to 
residues 199-1792, was cloned due to its recognition by two antibodies specific 
for heterogeneous nuclear ribonucleoproteins (hnRNPs) (Witte and Scott, 1997). 
Thus, RBQ-1, PACT, and P2P-R are in fact derivatives of the RbBP6 protein, 
which is the complete protein.  
 
Full length RbBP6 is a 250 kDa splicing-associated protein that, like SNAMA, 
contains the N-terminal DCM comprised of a DWNN domain, zinc finger, and 
RING finger motif. However, unlike the fly, both human and mouse RbBP6 
contain addition domains that include an SR domain, Rb-binding domain, and 
p53 binding domain (Simons et al., 1997; Witte and Scott, 1997) (Figure 5). As 
mentioned earlier, the presence of the di-glycine motif in the DWNN domain 
suggests that the domain may be involved in a similar process of conjugation as 
ubiquitin, which is known as DWNNylation (Pugh et al., 2006). Like SNAMA, 
RbBP6 contains an uncharacteristic RING finger motif, C3NC4, that is believed 
to exhibit ubiquitin ligase activity (Pugh et al., 2006). 
 
In humans, RbBP6 is expressed as three transcripts of 6.1, 6.0, and 1.1 kb, as a 
result of combined alternative splicing and alternative poly-adenylation (Pugh et 
al., 2006). These transcripts give rise to proteins of 1792, 1758, and 118 amino 
acids, designated RbBP6 isoforms 1, 2, and 3 respectively. The RbBP6 variant 3 
represents the DWNN domain that is expressed in vertebrates as a small protein 
of 118-150 residues containing a DWNN domain and a short C-terminal tail. 
Preliminary analysis suggests that the short form is present in all vertebrates but 
not in invertebrates, plants or fungi (Pugh et al., 2006). 
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1.6.1 RbBP6 function: a role in apoptosis  
 
RbBP6 and its derivatives are associated with and bind p53 and Rb in both 
humans and mice. RbBP6 is localized to chromosomes during mitosis and forms 
nuclear speckles, thought to be the main sites of activity for pre-mRNA splicing 
and processing during interphase (Gao et al., 2002). Overexpression of RbBP6 
has shown to lead to apoptosis (Gao and Scott, 2002; Scott et al., 2003). 
Knockdown of PACT (the truncated derivative of RbBP6) significantly 
decreases p53-Hdm2 interaction, reduces p53 poly-ubiquitination and 
degradation, and enhances p53 accumulation (Li et al., 2007). This increases p53 
levels, which leads to both apoptosis and cell growth retardation. Furthermore, 
disruption of PACT in mice leads to early embryonic lethality (Li et al., 2007). It 
has also been shown that RbBP6 is highly up-regulated in oesophageal cancer, 
and is thus a promising target for immunotherapy against the disease (Yoshitake 
et al., 2004). Taken together, these results indicate that the RbBP6-p53 
interaction plays a critical role in embryonic development and tumorigenesis and 
identifies RbBP6 as a member of negative regulators of p53.    
 
1.7 Ubiquitin 
 
Ubiquitin is a small, single domain protein of 76 residues. Its secondary 
structure consists of three and a half turns of alpha-helix, a short piece of 310-
helix, seven reverse turns, and a mixed beta-sheet containing five strands (Figure 
8). It thus forms a highly heat-stable, compact globular structure, with the last 
four C-terminal residues (Leu-Arg-Gly-Gly) extending away from the main 
body of the protein into aqueous space (Wilkinson et al., 1980). It is this “tail” 
that enables ubiquitin to covalently attach to other proteins and is thus vital in 
the functioning of ubiquitin. The ubiquitin structure was determined by X-ray 
crystallography and NMR (Vijay-Kumar et al., 1987; Weber et al., 1987). 
Ubiquitin folds by a simple two-state process in aqueous solution, 
uncomplicated by the formation of disulphide bonds or metal/cofactor binding 
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and with no accumulation of stable intermediates (Khorasanizadeh et al., 1993; 
Krantz and Sosnick, 2000).  
 
 
Figure 8. The native structure of ubiquitin. Ubiquitin consists of three and a half 
turns of α-helix (blue), a short piece of 310-helix (green), seven reverse turns 
(white strands), and a five stranded mixed β-sheet (yellow), (Vijay-Kumar et al., 
1987). 
 
Ubiquitin is a highly conserved polypeptide that is found in all eukaryotic 
organisms but not in either eubacteria or archaebacteria (Goldstein et al., 1975). 
It is found throughout the cell (hence its name) and can exist either in free form 
or as part of a complex with other proteins. In the latter case, ubiquitin is 
covalently attached to protein substrates and plays a fundamental role in the 
regulation of cellular function such as DNA repair, embryogenesis, cell cycle 
regulation, transcriptional regulation, and apoptosis (Lee and Tyers, 2001; 
Kirschner, 1999). In the nucleus, ubiquitin is covalently attached to histone 2A 
and is thought to participate in the regulation of transcriptional activity and/or 
chromatin structure. However, in the cytoplasm, ubiquitin targets protein 
substrates for degradation by the 26S proteasome (Pickart, 2001). The transfer of 
free ubiquitin onto a protein substrate is a multistep enzymatic process that 
ultimately leads to degradation of the target protein (Hershko and Ciechanover, 
1998). Ubiquitin and some ubiquitin-like proteins are cleaved at their di-glycine 
motif (G75 and G76) by specific hydrolases, thus initiating conjugation.  
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1.8 Ubiquitin-Proteasome Pathway 
 
The ubiquitin-proteasome pathway plays an important role in the degradation of 
short lived regulatory proteins (Peters, 1998), thereby maintaining homeostasis 
in the cell by regulating protein levels. These include proteins involved in the 
cell cycle, cellular signaling in response to stress and extracellular signals, 
morphogenesis, the secretory pathway, and DNA repair (Hershko and 
Ciechanover, 1998; Weissman, 1997). Degradation of a protein via the 
ubiquitin-proteasome pathway involves two discrete and successive steps: 
tagging and degradation. The target protein is first “tagged” by the covalent 
attachment of multiple ubiquitin molecules. The “tagged” protein, which now 
contains a polyubiquitin chain, is then recognized by the 26S proteasome. The 
proteasome, which is a proteolytic complex, degrades the “tagged” protein and 
releases inactive peptides together with free, reusable ubiquitin (Ciechanover, 
1998) (Figure 9).  
 
The first step of the ubiquitin-proteasome pathway requires three enzymes that 
function in a cascade mechanism to allow the covalent attachment of the 
ubiquitin to the substrate (Figure 9). Initially, ubiquitin is activated by the 
ubiquitin activating enzyme (E1). This is an ATP-dependent reaction that results 
in a high-energy thioester bond forming between a cysteine, in the active site of 
E1, and the C-terminal glycine (G76) of ubiquitin (Haas and Rose, 1982). The 
activated ubiquitin is then transferred from E1 to a specific ubiquitin conjugating 
enzyme (E2) through yet another thioester bond (Hershko et al., 1983). An 
ubiquitin ligase (E3), which interacts with both the E2 and the target protein, 
then catalyzes the isopeptide bond formation between the C-terminal glycine in 
ubiquitin and the lysine residue in the protein substrate (Hershko and 
Ciechanover, 1998). The isopeptide bond forms between the α-carboxyl group 
of the glycine and the ε-amino group of the lysine side chain.  
 
Ubiquitin molecules are then attached in succession, through the binding of the 
terminal carboxyl of each ubiquitin with the lysine residue of the adjacent 
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ubiquitin, to form a polyubiquitin chain. A chain of 4 or more ubiquitin 
molecules, linked via K29 or K48, targets proteins for degradation by the 26S 
proteasome. There are a number of different classes of E3 enzymes that serve to 
regulate the interaction between E2 proteins and the various protein substrates. 
Thus the ubiqutin ligases play a key role in ubiquitin conjugation pathway. 
-  
 
Figure 9. Degradation of proteins via the ubiquitin-proteasome pathway. 
Ubiquitin is transferred to the ubiquitin activating enzyme (E1) in an ATP-
dependent manner. The ubiquitin is then transferred to an ubiquitin conjugating 
enzyme (E2). The ubiquitin ligase binds both the E2 and the target protein, thus 
allowing for the covalent attachement of the ubiquitin molecule to the target 
protein. Ubquitin molecules are then added in succession until a chain or 4 or 
more residues is reached, at which point the target protein is transported to the 
26S proteasome for degradation.       
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1.9 Ubiquitin Ligases, the E3s 
 
Ubiquitin ligases, E3s, are by definition enzymes that bind specifically to protein 
substrates, and promote the transfer of ubiquitin from a thioester intermediate to 
the target protein or ubiquitin molecules thus forming polyubiquitin chains 
(Hershko and Ciechanover, 1998). The E3s are a large family of proteins that 
exist as single polypeptides or multimeric complexes. They are separated into 
three major and structurally distinct classes: the N-end rule E3s, the E3s 
containing the HECT (Homology to E6AP C-Terminus) domain, and the RING 
finger E3s, which include its derivatives the U-Box and the PHD (Plant Homeo-
Domain) (Sun, 2003). The N-end rule E3s are found rarely and are involved in 
ubiquitin conjugation to the N-terminal amino group of the protein substrate 
(Varshavsky, 2003). An example of an N-end rule E3 is DIAP1, which is 
involved in the Drosophila programmed cell death system (Ditzel et al., 2003).  
 
HECT family E3s rely on the transfer of ubiquitin from the E2 to a cysteine 
residue in the active site of the E3, through a third high-energy thioester bond. 
The HECT E3 then transfers the ubiquitin molecule to the protein substrate 
(Glickman and Ciechanover, 2002). HECT family E3s include E6-AP (E6-
associated protein), which targets p53 for ubiquitination in the presence of 
human papilloma virus E6 (Schneffner et al., 1993), and Nedd4. 
 
The most common class of E3s, namely the RING finger E3s, catalyze the direct 
binding of the activated ubiquitin on E2 to the target protein (Figure 9). This is 
achieved through specific binding of both the E2 and the protein substrate to the 
RING finger, thus bringing the ubiqutin molecule into close enough proximity 
with the target protein for binding to occur. The U-box domain proteins, the E4s, 
also facilitate in the formation of polyubiquitin chains on target proteins, either 
independently of an E3 (Hatakeyama et al., 2001) or in some instances requiring 
an E3 (Koegl et al., 1999). The U-box domain forms a RING finger fold yet 
portrays ubiquitin ligase activity in the absence of divalent cations. Furthermore, 
U-box domains utilize lysine residues on ubiquitin for poly-ubiquitination like 
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that not used by HECT and RING finger domain E3s. Thus, there is much 
speculation of whether E4s form a new class of E3s, independent of the RING 
finger ligases, or whether they are derivatives of RING finger domain that form 
a subset of this class.   
 
The PHD domain also resembles the RING finger domain but unlike the 
characteristic RING finger it contains eight conserved metal binding ligands 
with similar spacing (Lu et al., 2002). The PHD domain is found in many 
proteins involved in chromatin-mediated transcriptional regulation, however 
very little is known about their exact functions (Aasland et al., 1995).     
 
E3s are enzymes that determine the specificity of protein substrates, and 
therefore represent a class of “drugable” targets for pharmaceutical intervention. 
Ubiquitin ligases are overexpressed in a number of human cancers and their 
inhibition leads to growth suppression or apoptosis (Sun, 2003). It is anticipated 
that ubiquitin ligases, in particular the RING finger ubiquitin ligases, will 
present an important new target platform for future mechanism-driven drug 
discovery due to their specificity for both the E2 and target protein.   
 
1.9.1 RING finger E3s 
 
Classical RING finger motifs are small zinc binding domains that are found 
within larger, functionally distinct proteins, often close to the N- or C-terminal. 
There are hundreds of known RING finger domain proteins (more than 350 in 
humans alone) (Furukawa et al., 2002), which were originally discovered by 
Paul Freemont and his colleagues (Freemont et al., 1991). Freemont showed that 
all RING finger domains contain the conserved sequence Cys-X2-Cys-X9-39-Cys-
X1-3-His-X2-3-Cys/His-X2-Cys-X9-39-Cys-X2-Cys, where X is any amino acid 
(Saurin et al., 1996) (Figure 7A). RING finger domains are defined by this 
pattern of conserved Cys and His residues that co-ordinate two zinc ions to form 
a “cross-brace” structure (Borden, 2000; Saurin et al., 1996). The varying length 
and sequence between the conserved Cys and His residues, as well as metal 
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chelating residues being substituted with others, accounts for the differences 
among RING finger domains. 
  
As mentioned earlier, RING finger ubiquitin ligases interact with both the E2 
and the target protein and catalyze the direct formation of a covalent bond 
between ubiquitin and the protein substrate (Figure 9). Crystal structures of 
RING finger ubiquitin ligases have shown that E2 binds to the RING domain 
through contacts between a groove in the RING domain and two loops in the E2 
fold (Zhou and Howley, 1998). Furthermore, the structure reveals a rigid 
coupling between the target protein-E3 complex and the E2-E3 complex with a 
conserved surface channel leading from the target protein to the E2 active site. 
This indicates that RING finger ubiquitin ligases function as scaffolds that 
position the substrate and the E2 optimally for ubiquitin transfer. Following this 
discovery, the function of many more RING finger ligases have been shown to 
be dependent on their RING finger motif (Lorick et al., 1999). Thus, it is 
suspected that all RING finger containing proteins act as ubiquitin ligases that 
facilitate in the ubiquitination of target proteins.  
 
RING finger ligases are separated into two distinct groups: the single subunit 
ubiquitin ligases and the multi-subunit ubiquitin ligases. The single subunit E3s 
are monomers or homodimers that contain both the RING finger domain and the 
substrate-binding site in the same molecule, such as Mdm2 and Parkin (Lorick et 
al., 1999; Shimura et al., 2000). The multi-subunit enzyme, which include the 
APC (anaphase-promoting complex), the VBC (von-Hippel Lindau-Elongins B 
and C), and the SCF (Skp1-Cullin/Cdc53-F-box protein), function in complexes 
with proteins of the cullin family and other ancillary proteins. The cullin proteins 
promote the assembly of these multi-subunit enzymes, whereas the other 
ancillary proteins function in substrate recognition. 
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1.9.2 U-Box domain ubiquitin ligase, E4s 
 
The U-box is a domain of approximately 70 amino acids that is present in 
proteins from yeast to humans (Hatakeyama et al., 2001). The prototype U-box 
protein, yeast Ufd2 (ubiquitin fusion degradation), is essential for the assembly 
of polyubiquitin chains on artificial substrates that are targeted for degradation 
(Koegl et al., 1999). The U-box is essentially a modified RING finger that lacks 
many of the conserved metal chelating cysteine residues normally found in 
RING finger domains (Aravind and Koonin, 2000). Rather, the U-box fold, 
which mimics that of the RING finger, is stabilized by salt-bridges, hydrogen 
bonds, and conserved hydrophobic residues within its consensus. 
 
Proteins that contain the U-box domain are referred to as E4s. Some believe that 
E4s form an additional subset of RING finger ligases (Koegl et al., 1999; 
Aravind and Koonin, 2000). Others believe that E4s define a new class of E3s, 
independent of the HECT and RING finger E3s (Hatakeyama et al., 2001). In 
either case, U box proteins facilitate the formation of polyubiquitin chains on 
target proteins due to its RING finger conformation (Koegl et al., 1999).  E4s 
can function as ubiquitin ligases in the absence of an E3 (Hatakeyama et al., 
2001), or in some instances they require an E3 (Koegl et al, 1999). At least six 
mammalian E4s have been shown to mediate polyubiquitination in the presence 
of an E1 and a specific E2 but absence of E3 (Hatakeyama et al., 2001). 
Furthermore, deletion of the U-box or mutation of conserved amino acids within 
its conserved sequence, abolishes ubiquitination activity.  
 
The characteristic RING finger E3s require divalent cations for ubiquitin ligase 
activity (Freemont, 1993). In contrast, the E4s portray ubiquitin ligase activity in 
the absence of divalent ions such as zinc. The U-box proteins also appear to 
catalyze their own ubiquitination. Interestingly E4s have been shown to utilize 
multiple lysine residues of ubiquitin, in addition to normal K29, K48, or K63, to 
mediate the formation of polyubiquitin chains (Hatakeyama et al., 2001). It is 
not clear yet whether E4s, like the RING finger E3s, are involved in recruiting 
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E2 or whether it binds to the short ubiquitin chain conjugated to the target 
protein.   
 
1.10 Deubiquitinating Enzymes (DUBs) 
 
Deubiquitinating enzymes (DUBs) are specific proteases that recognize 
ubiquitin and cleave the isopeptide bond formed by the last glycine residue in an 
ubiquitin molecule. There are at least five families of DUBs: ubiquitin C-
terminal hydrolases (UCHs), ubiquitin specific proteases (USPs), MJD 
(Machado-Joseph disease) proteases, OTU (Otubain) proteases, and JAMM 
(JAB1/MPN/Mov34 metalloenzyme) motif metallo-proteases (Nijman et al., 
2005). The first four families are cysteine proteases, while JAMMs are zinc-
dependent metalloproteases. UCHs are 20-30 kDa enzymes that remove short or 
flexible peptide chains from the C-terminus of ubiquitin. UBPs are 
approximately 100 kDa enzymes that cleave the isopeptide bonds of ubiquitin-
ubiquitin or ubiquitin-protein fusions. Both groups of enzymes contain 
conserved cysteine, histidine, and aspartate residues within their active site, but 
differ in that their consensus sequence is divergent (D’Andrea and Pellman, 
1998). As mentioned earlier, ubiquitin is not synthesized directly as free 
ubiquitin but rather as linear fusions either to itself or to certain ribosomal 
proteins. DUBs function in maintaining the steady-state levels of free ubiquitin 
by cleaving ubiquitin from ubiquitin-protein or ubiquitin-ubiquitin complexes 
(Chung and Baek, 1999; D’Andrea and Pellman, 1998). Thus, DUBs play a role 
in the generation of ubiquitin, recycling of ubiquitin, editing polyubiquitin 
chains, and aiding in proteasome-dependent degradation.    
 
Originally, the ubiquitin-proteasome pathway was thought to be unidirectional 
from substrate ubiquitination to degradation by the 26S proteasome. However, 
the discovery of deubiquitinating enzymes (DUBs) changed the global view of 
the enzymatic process and showed the incredible dynamics of this pathway. The 
finding that the herpes virus-associated ubiquitin-specific protease (HAUSP) 
could bind to and stabilize p53 illustrated the greater dynamics of the p53 
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proteasome-pathway and was one of the first indications that DUBs exhibited 
substrate specificity (Hu et al., 2002). A growing number of substrate-specific 
mammalian DUBs involved in tumorigenesis are continually being revealed 
such as USP1 and USP9X, which deubiquinate FANCD2 and β-catenin 
respectively (Nijman et al., 2005). In the proteasome there are regulatory 
particles that have DUB activity and are responsible for removal of ubiquitin 
from protein substrates (Eytan et al., 1993). In Drosophila, the regulatory 
particle subunit responsible for this activity is p37a (Hölzl et al., 2000).  
 
1.11 The ubiquitin-like Superfamily  
 
Following the discovery of ubiquitin a number of proteins have been identified 
that are related to ubiquitin, or function similarly to modify proteins through 
their covalent attachment to protein substrates. This ubiquitin-like superfamily is 
divided into two groups. Proteins within the first group are known as ubiquitin-
like proteins (UBLs). UBLs are similar to ubiquitin in that they modify other 
proteins by covalent attachment of themselves to amino acid residues on the 
target protein. Furthermore, the conjugation pathway and sites of attachment of 
these proteins onto target proteins resemble the ubiquitin conjugation pathway. 
Proteins within the second group are referred to as ubiquitin domain proteins 
(UDPs). UDPs contain protein domains that are related to ubiquitin. However, 
these protein domains are not related to ubiquitin in sequence, nor are the 
proteins conjugated to other proteins like ubiquitin.  
 
1.11.1 Ubiquitin-like proteins (UBLs) 
 
UBLs, like ubiquitin, are expressed as inactive precursors that are activated by 
proteolytic cleavage of the C-terminus, thus exposing the C-terminal di-glycine 
motif needed for conjugation. The di-glycine motif is important for the 
recognition and activation of the conjugation process by the activation enzyme 
E1. The conjugation pathways for the UBLs are very similar to that of ubiquitin. 
Like ubiquitin, they require their own enzymes E1 and E2, and attach to the 
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target protein through an isopeptide bond with a lysine residue of the substrate. 
The activating enzyme, E1, activates the UBL followed by the transfer of the 
UBL to the conjugating enzyme, E2, via a thiol-ester bond. Although the steps 
and reactions involved in the activation of ubiquitin and UBL are similar, the E1 
and E2 enzymes cannot replace each other. All known UBLs are homologous to 
ubiquitin in some regard, with the exception of APG12 and URM1 (ubiquitin 
related modifier). NEDD8/Rub1 shows 60% identity to ubiquitin, 
SUMO/Smt3p/sentrin shows ~20% identity to ubiquitin, and APG12/URM1 
shows no sequence homology whatsoever. APG12 and URM1 are therefore only 
grouped with UBLs since they are small protein modifiers that are activated and 
conjugated to target proteins in a similar manner to ubiquitin.   
 
SUMO 
 
The transfer of SUMO (small ubiquitin-like modifier) to target proteins involves 
the E1 heterodimer Aos1-Uba2, a single E2 enzyme Ubc9 (Johnson et al., 1997; 
Johnson and Hochstrasser, 1997), and in yeast a specific E3 (Johnson and Gupta, 
2001). Several SUMO molecules can attach to the target protein at distinct sites, 
but unlike ubiquitin, multi SUMO chains do not form on the substrate (Jentsch 
and Pyrowolakis, 2000). In addition, the attachment of SUMO to target proteins, 
referred to as sumoylation, does not target proteins for degradation. Sumoylated 
proteins are however found in the nucleus or nuclear envelope, as shown with 
sumoylated PML (Kamitani et al., 1998), SP100, RanGAP1, p53, and IКBα (Yeh 
et al., 2000). This suggests that attachment of SUMO to substrates targets them 
for transfer to the nucleus similarly to ubiquitinated proteins. 
 
RUB 
 
RUB (related to ubiquitin) shows 50% homology to ubiquitin with homologs 
found in all eukaryotes (Liakopoulos et al., 1998). These homologs include the 
S. cerevisiae protein Rub1, and the human protein NEDD8. Like SUMO, RUB 
is also related to the ubiquitin pathway as it is conjugated to proteins by process 
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known as rubylation. Rubylation occurs in the presence of a heterodimeric E1, 
ULA1/UBA1, and an E2, Ubc12 (Hori et al., 1999). The target proteins of RUB 
proteins are limited to a small number of proteins that are part of the cullin 
protein family. Rub1/NEDD8 conjugates to Cdc53/Cul-1, which are components 
of the SCF E3 ubiquitinating complex. This conjugation stabilizes the interaction 
between Cdc53/Cul-1 with E2s such as Cdc34 or Ubc4 and to a variety of F-box 
proteins (Kawakami et al., 2001; Liakopoulos et al., 1998). Thus, RUB 
ubiquitin-like proteins play a general role in down regulating SCF activity 
(Glickman and Ciechanover, 2002).  
 
APG12 and URM1 
 
APG12 conjugation to the target protein Apg5 involves the E1 enzyme Apg7, 
and the E2 enzyme Apg10. Interestingly, Apg7 is related in sequence to the E1 
of the ubiquitin conjugation pathway, however the Apg10 differs from the 
ubiquitin E2s. The conjugated protein plays a role in autophagosome vesicle 
formation and delivery of cytoplasmic material to the lysosome (Furukawa et al., 
2000). URM1 is a 99 amino acid protein ending with the di-glycine residue 
found in ubiquitin and other UBLs (Furukawa et al., 2000). This provides URM1 
with a means of conjugation to target proteins through hydrolysis of the peptide 
bond. The identification of Apg12 and URM1 indicates that other UBLs may 
exist that cannot be identified by sequence homology to ubiquitin but rather need 
to be identified by functional similarities. 
 
1.11.2 Ubiquitin domain proteins (UDPs)  
 
UDPs are large proteins that contain a distinct ubiquitin-like domain within their 
sequence. The ubiquitin-like domain does not always end in the di-glycine motif 
and is thus not processed by DUB proteases as ubiquitin, but they do show 
sequence homology to ubiquitin and are linked to the ubiquitin conjugation 
pathway (Jentsch and Pyrowolakis, 2000).  These UDPs include the Xenopus 
Scythe (Thress et al., 1998), Parkin (Morett and Bork, 1999), and the UIP28 
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protein (Martinez-Noel et al., 1999). One must keep in mind that UDPs such as 
Parkin and UIP28 contain an ubiquitin-like domain amongst other domains that 
include RING fingers. It is therefore possible that the activity portrayed by the 
protein is not entirely due to the ubiquitin-like domain but rather more due to 
other domains within the protein. It is likely the ubiquitin-like domain of most 
UDPs, especially those where the di-glyine motif is absent, facilitates processes 
such as ubquitination in terms of recognition and binding to target proteins or 
ubiquitin molecules.    
 
UDPs have also been shown to play a role as adaptors linking the ubiquitin 
pathway to the proteasome, sometimes with the aid of chaperones (Kleijnen et 
al., 2000). This process occurs via the association between the ubiquitin-like 
domain within the UDPs and other characterized domains within the 
proteasome. Three such UDPs include Rad23, Dsk2, and Bag-1 (Lambertson et 
al., 1999; Lüders et al., 2000). The replacement of the ubiquitin-like domain in 
Rad23 with ubiquitin demonstrates the structural importance of this ubiquitin-
like domain and not its sequence identity to ubiquitin in binding the proteasome 
(Watkins et al., 1993). The yeast Rad23 and Dsk2 UDPs overlap functionally 
with respect to their involvement in the spindle pole body duplication, with 
Rad23 having an additional role in DNA repair (Biggins et al., 1996).       
 
HUB (homologous to ubiquitin) is a UDP that functions similarly to ubiquitin by 
attaching itself to target proteins. It has a 22% sequence homology to ubiqutitin 
but lacks the di-glycine motif at the C-terminal end of its ubiquitin-like domain 
(Lüders et al., 2003). However, the highly conserved HUB proteins contain a C-
terminal di-tyrosine motif followed by a nonconserved single amino acid. 
Homologs in humans and yeast include UBL5 and HUB1 respectively (McNally 
et al., 2000), with HUB1 being shown to fold similarly to that of ubiquitin 
(Ramelot et al., 2003). Although HUB shows sequence similarity and folding to 
ubiquitin its mechanism of attachment to target protein does not involve covalent 
bonding. This was shown by HUB1, which forms SDS-resistant complexes with 
target proteins (Lüders et al., 2003). These complexes are not formed through 
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covalent C-terminal conjugation thus disagreeing with an ubiquitin-like 
conjugation mechanism for HUB1. It suggests rather that attachment of the 
HUB1 UDP occurs via a different, possibly non-enzymatic process.          
  
 1.12 Aims 
 
The main focus of this work is to further elucidate the functional characteristics 
of the DCM within SNAMA. This will be achieved in two ways. Firstly, the way 
in which gene regulation of SNAMA is controlled will be examined. Secondly, 
and more importantly, it will be determined whether the DCM of SNAMA 
exhibits ubiquitin ligase activity and if so what factors affect this activity.    
 
Transcriptional regulation of SNAMA will be determined by analysing the core 
promoter elements that surround the transcription start site of the gene. The 
transcription initiation site of SNAMA will be established by performing 5´  
RACE using Drosophila RNA and gene specific primers. This will allow for 
analysis of the 5´  region of the SNAMA gene by ensuring the amplification of 
capped transcripts.  
 
SNAMA ubiquitin ligase activity will be confirmed by ubiquitin conjugation 
assays using a pure and active recombinant SNAMA protein as the E3.  This 
would allow SNAMA to catalyze the covalent attachment of ubiquitin to both 
itself as well as other target proteins. The dependence of SNAMA activity on its 
RFL motif will be examined in unison with determining the specific E2 that 
allows SNAMA to function with optimal activity. Thereafter, the dependence of 
SNAMA activity on key components of the ubiquitination process including E1, 
zinc ions, ATP, and ubiquitin, will be determined. In order to achieve this goal a 
pure and active form of the conserved N-terminal DCM of SNAMA will be 
needed. This promises to be challenging as heterologous protein expression of 
SNAMA in E. coli forms insoluble inclusion bodies.   
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This characterization of the RFL motif and DWNN domain will facilitate the 
determination of the overall function of SNAMA and provide insight into its role 
in apoptosis, particularly its relationship to Dmp53. Since the mechanisms and 
regulation of apoptosis are highly conserved throughout evolution, studies of 
apoptosis in Drosophila may provide new insight for understanding defective 
regulation of apoptosis in diseases such as cancer.    
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2. MATERIALS AND METHODS  
 
2.1 Growth Media 
 
Table 2. Growth media. 
 
Media Composition 
Apple juice agar 1.25% sucrose; 2% agar; 0.025% streptomycin; 
0.15% methylparaben (3g dissolved in 30 ml 
ethanol and made up to a litre); 25% apple juice 
(v/v). 
Luria-Bertani broth (LB) 1% tryptone powder; 0.5% yeast extract powder; 
1% NaCl; mix and autoclave. 
LB agar (LA) LB + 1.5% agar; autoclave. 
 
2.2 Buffers and Solutions 
 
Table 3. Molecular biology buffers and solutions. All reagents were stored at 
room temperature and made up with deionised water unless otherwise indicated. 
 
Buffer Composition 
Coomassie blue stain 0.1% Coomassie blue R-250; 40% ethanol; 
10% glacial acetic acid. 
Denaturation buffer 8 M Urea; 50 mM sodium phosphate 
buffer, pH 8.0; 100 mM NaCl; 1 mM 
PMSF and 2 mM DTT on day of use.  
Dialysis (refolding) buffer 50 mM Sodium phosphate buffer, pH 8.0; 
100 mM NaCl; 5 mM EDTA; 5 mM 
cycolodextrin; 50 mM arginine. 
DNA loading dye (10X)  0.21% Bromophenol blue; 0.21% xylene 
cyanol FF; 50% glycerol; 0.2 M EDTA, 
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pH 8.0; store at 4ºC.  
Electrode (running) buffer (5X) 125 mM Tris base; 1 M glycine; 17 mM 
SDS; pH to 8.3 with HCl.    
Lysis buffer 50 mM Tris-HCl, pH 7.5; 2 mM EDTA, 
pH 7.5; 200 mM NaCl; add 0.1 mM PMSF 
and 200 µg/ml fresh lysozyme immediately 
prior to use.  
Miniprep solution I 5 mM sucrose; 10 mM Na2EDTA-2H20; 
25 mM tris; pH to 8.0 with NaOH.  
Miniprep solution II 0.2 M NaOH; 1% SDS; prepare fresh. 
Miniprep solution III 3 M sodium acetate, pH 4.8 made up with 
acetic acid. 
Phosphate buffered saline (PBS), 
50X  
1.4 M NaCl, 27 mM KCl, 101 mM 
Na2HPO4, 18 mM KH2PO4, pH to 7.3 
with HCl. 
RIPA buffer 1% Nonidet p-40; 1% sodium 
deoxycholate; 0.1% SDS; made up with 
1X PBS; add 0.5 mM PMSF on day of use. 
SDS sample buffer (5X) 1 M Tris-HCl, pH 6.8; 10% glycerol; 10% 
SDS; β-mercaptoethanol; 1% bromophenol 
blue; store at 4ºC. 
TAE: Tris acetate EDTA (50X) 2 M Tris base; 5.71% glacial acetic acid; 
50 mM EDTA, pH 8.0. 
Towbin buffer 25 mM Tris base; 192 mM glycine; 0.1% 
SDS; pH to 8.3 with HCl; 20% (v/v) 
methanol on day of use. 
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2.3 Chemicals and kits 
 
Table 4. Chemicals, kits and their suppliers. All chemicals used during the 
project were of analytic grade and if not mentioned were purchased from either 
Sigma-Aldrich (South Africa) or Merck Biosciences (South Africa). 
 
Supplier Chemical/Kit 
BIO-RAD  Bio-Rad protein assay reagent. 
Boehringer Tetracycline (Tet).  
Calbiochem (Merck Biosciences) Ubiquitin, recombinant GST-fusion in E. 
coli; ubiquitin-activating enzyme E1, 
human GST-fusion; ubiquitin conjugation 
enzyme set.  
Fermentas GeneRulerTM 100bp DNA ladder plus; 
PageRulerTM prestained protein ladder.   
Invitrogen GeneRacerTM kit; TOPO TA® cloning kit; 
TRIzol® reagent; SuperScriptTM II reverse 
transcription system.  
Millipore Stirred Ultrafiltration Cell 
Novagen (Merck Biosciences) BugBuster® Protein Extraction Reagent; 
iFOLDTM Protein Refolding System 1.  
Pierce SnakeSkinTM pleated dialysis tubing; 
Slide-A-Lyzer® dialysis cassettes; 
SuperBlock® dry blend (TBS) blocking 
buffer; SuperSignal West Pico 
Chemiluminescent Substrate.  
Promega pGEM®-T Easy vector system; ImProm-
IITM reverse transcription system.   
Roche Applied Science Chloramphenicol (Cm); kanamycin (Kan). 
Stratagene  E. coli XL-1 Blue and BL21(DE3)pLysS 
cells. 
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2.4 Bacterial Strains 
 
Table 5. Bacterial strains. 
 
Strain Genotype 
Escherichia coli XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 
supE44 relA1 lac [F´ proAB lacIqZ∆M15 
Tn10 (Tetr)] 
Escherichia coli BL21(DE3)pLysS  F- ompT hsdSB (rB - mB-) gal dcm 
λ(DE3)pLysS T1R 
 
2.5 Oligonucleotides 
 
Oligonucleotides were purchased from Inqaba biotec unless otherwise stated. 
The GeneRacerTM 5´  primer and 5´  nested primer were supplied with the 
GeneRacerTM kit.  
 
Table 6. Oligonucleotides used during PCR, RT-PCR, and sequencing. 
Restriction enzymes that were incorporated into the primers are underlined. 
 
Oligonucleotide Sequence 
DWNN forward 5´-TTCATATGGATCCATGTCGGTACACTAT-3´  
GeneRacerTM 5´   5´ -CGACTGGAGCACGAGGACACTGA-3´  
GeneRacerTM 5´ nested  5´ -GGACACTGACATGGACTGAAGGAGTA-3´  
M13 reverse 5´ -CAGGAAACAGCTATGAC-3´  
RING finger reverse 5´ -CGAACAAAGCTTCTCCTTGCAATCG-3´  
RF tail  5´ -AGTGAGTGCCCCGATTGCAAGGAG-3´  
RF tail internal 5´ -CCGCAGCAGGGTATCATGACAGCAT-3´  
T7 5´ -TAATACGACTCACTATAGGG-3´  
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2.6 Total RNA Extraction From Wild-Type D. melanogaster 
 
Wild-type Canton-S Drosophila melanogaster flies were reared at 25ºC on 
standard cornmeal agar food with yeast added. For extraction of total RNA, 50 
wild-type adult fruit flies were selected and homogenized in a 1.5 ml eppendorf 
tube using 500 µl TRIzol reagent. 150 µl chloroform was added to the 
homogenate and centrifuged at 13 000 x g for 10 minutes at 4ºC. The 
supernatant was retained and mixed with 350 µl isopropanol, left at room 
temperature for 2 minutes, and spun at 13 000 x g for 15 minutes at 4ºC. The 
supernatant was removed and the pellet resuspended in 200 µl ice-cold 70% 
ethanol after which it was centrifuged again for 15 minutes at 13 000 x g. The 
ethanol was removed by aspiration and the pellet allowed to dry for 3 minutes at 
37ºC. The dried RNA pellet was resuspended in 50 µl of sterile, RNAse free 
water, heated at 65ºC for 10 minutes, and its concentration determined. 20 µg of 
RNA was then aliquoted into eppendorf tubes and placed at –20ºC until needed. 
 
2.7 5´ Rapid Amplification of cDNA Ends (5´ RACE) 
 
5´  RACE was used to determine the transcriptional start site and possible 
internal promoter regions of the SNAMA gene. 5´  RACE involved a number of 
consecutive steps that included the removal of 5´ - phosphates and 5´ -caps from 
RNA, followed by ligation of the GeneRacerTM RNA oligonucleotide, reverse 
transcription (RT), and polymerase chain reaction (PCR) respectively. All steps 
during 5´  RACE were carried out essentially as described in the GeneRacerTM 
kit, unless otherwise indicated.  
 
(a) Removal of 5´ -terminal phosphates: Approximately 5 µg of total RNA 
from Drosophila, together with 1 µg HeLa mRNA from normal human tissues 
(as a positive control), was treated with calf intestinal phosphatase (CIP) to 
eliminate the 5´ -terminal phosphates. 
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(b) Removal of 5´-caps: Tobacco acid pyrophosphatase (TAP) was used to 
remove the 5´ -cap structure from the dephosphorylated RNA. 
 
(c) Ligation of GeneRacerTM oligonucleotide: Removal of the 5´cap exposes 
the 5´-phosphate, which allows for the ligation of the GeneRacer RNA oligo to 
the decapped RNA in the presence of T4 RNA ligase.   
 
(d) Reverse transcription: The ImProm-IITM or SuperScriptTM II reverse 
transcription systems were used to generate cDNA from Drosophila RNA and 
the HeLa control mRNA. The RF tail primer was used as a gene-specific primer 
during the Drosophila RNA reverse transcription reaction, while an oligo(dT) 
primer was used for reverse transcription of the HeLa control mRNA. Extension 
temperatures for these reactions were 55ºC and 42ºC respectively.    
 
(e) GeneRacerTM PCR: The PCR procedure for 5´ RACE is slightly different 
to that generally used. The reaction mixture consisted of 2 mM MgCl2, 0.2 mM 
dNTP mix, 0.6 µM GeneRacerTM primers, 1 µM RF tail and RF tail internal 
primers, and 5 U Taq polymerase (section 2.12). In contrast, the cycling 
conditions were: 
 
 
The PCR products generated from 5´  RACE were then run on an agarose gel, 
and the bands extracted, cloned and sequenced.  
 
2.8 Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis is a technique that allows one to separate DNA and 
visualize the fragments as bands in the gel, therefore allowing DNA to be 
analyzed qualitatively. A 1% or 1.5% agarose gel, cast in 1X TAE buffer, was 
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used with between 0.5 and 1 µg of ethidium bromide added. Between 5 and 15 
µg of DNA, mixed with 1X DNA loading dye, was added to the wells of the 
agarose gel. Electrophoresis was performed in a 1X TAE running buffer at a 
voltage of between 55 and 70 V. The DNA fragments within the gel were then 
visualized under UV light, and their image photographed, using the UVP 
BioDoc-ItTM system. The size of the DNA fragments were then determined 
through visual comparison with the molecular weight markers or with the aid of 
a standard curve, constructed using the molecular weight markers.     
 
2.9 DNA Extraction from Agarose Gel 
 
DNA was excised from the agarose gel and purified using the GenEluteTM Gel 
Extraction kit from Sigma. DNA was extracted following the procedure provided 
by the manufacturer. The kit combines silica based-membrane technology and the 
convenience of a spin column format to capture and purify the DNA from the gel.  
  
2.10 Cloning  
 
Cloning of DNA involved the ligation of a PCR product into a TA cloning 
vector and transformation into competent E. coli XL-1 Blue cells. The PCR 
product is in a more stable state and environment when incorporated in a 
plasmid within bacterial cells. The antibiotic resistance supplied by plasmids and 
cells also allows for accurate selection of transformed cells. Cloning an insert 
into an expression vector was more complex. Initially, the PCR product was 
cloned into a TA cloning vector, after which the fragment was restricted out with 
specific endonucleases, ligated into the pET41(a) expression vector, and 
transformed into E. coli BL21(DE3)pLysS cells. This allows the fragment to be 
inserted into the expression vector in the correct orientation and in-frame with 
the GST-gene.     
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2.10.1 Ligation 
 
Purified PCR products were ligated into the pGEM®-T Easy or pCR®4-TOPO® 
TA cloning vectors using the pGEM®-T Easy vector TA-cloning system I and 
TOPO TA® cloning kit respectively (Appendix V). Both systems use T4 DNA 
ligase to ligate the PCR product, containing TA overhangs, into the TA cloning 
vector.  
 
Ligation of the DCM of SNAMA into the pET41(a) expression vector 
(Appendix VI) initially involved the restriction of the fragment out of the 
cloning vector.  The fragment was separated from the cloning vector through 
restriction with BamHI and HindIII, after which the fragment was ligated into 
pET41(a) using T4 DNA ligase. Prior to ligation, pET41(a) was also restricted 
with BamHI and HindIII, and dephosophorylated with alkaline phosphatase. 
This provided free phosphate groups needed for ligation of the fragment and 
insured that the fragment was inserted in the correct orientation.  
 
2.10.2 Preparation of chemically competent cells 
 
Chemically competent E. coli XL-1 Blue and BL21(DE)3pLysS cells were 
prepared by following a slightly altered procedure designed by the Fred 
Hutchinson Cancer Research Center. A single bacterial colony was used to 
inoculate 5 ml of LB and incubated overnight at 37°C with vigorous shaking. 
Following incubation, the starter culture was diluted 100X with 250 ml LB, 
supplemented with the appropriate antibiotic. The culture was then shaken at 
37ºC until an OD600 of between 0.5 and 0.6 was reached, at which point they 
were transferred to GSA bottles and centrifuged at 5000 x g for 10 minutes at 
4ºC. The supernatant was removed and the pellet resuspended in 100 ml of ice-
cold 100 mM MgCl2. This was followed by a 30 minute incubation on ice after 
which the cells were again pelleted by centrifugation at 4000 x g for 10 minutes 
at 4°C. The supernatant was discarded and cells resuspended in 10 ml of ice-cold 
100 mM CaCl2 containing 15% glycerol. The now competent cells were 
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aliquoted into small pre-cooled eppendorf tubes (200µl/tube) and stored, for a 
period of no longer than 6 months, at -70°C. 
 
2.10.3 Transformation 
 
The ligation reaction mixture of 10µl, containing approximately 50 ng of vector 
with insert, was added to 90µl of competent E. coli cells. The mixture was then 
incubated on ice for 20 minutes and heat shocked for 10 minutes at 37ºC, which 
caused the cells to take in the recombinant plasmids. The transformed cells were 
made up to 1 ml with 900 µl LB and shaken gently for 1 hour at 37ºC to allow 
for regeneration. 70 µl of transformed cells were then spread on LA-appropriate 
antibiotic plates, to select for those cells that took up the resistant recombinant 
plasmid. These plates were then incubated overnight at 37ºC. 
 
2.11 Small Scale Preparation of Plasmid DNA (Miniprep) 
 
The procedure for small scale preparation of plasmid DNA was derived from that 
published by Birnboim, 1983. A single bacterial colony containing the desired 
plasmid was used to inoculate 2 ml of LB, supplemented with the appropriate 
antibiotic, and incubated at 37ºC overnight with vigorous shaking. The next day 
the cells were harvested by centrifugation at 13 000 x g for one minute. The cells 
were resuspended in 100 µl of Miniprep solution I and then 200 µl Miniprep 
solution II, mixed, and incubated for 3 minutes at room temperature. 150 µl of 
Miniprep solution III was then added, mixed, and incubated on ice for 20 minutes. 
Following incubation, the mixture was microfuged at 13 000 x g for 5 minutes 
and the supernatant retained. RNA was removed through the addition of 50 µg 
RNaseA and incubation for 5 minutes at room temperature.  
 
To remove protein contaminants an equal volume of phenol: chloroform: isoamyl 
alcohol (25:24:1) was added to the solution, mixed, and microfuged for 5 minutes 
at 13 000 x g. The aqueous layer was transferred to a fresh tube and an equal 
volume of chloroform added and mixed, before microfuging at 13 000 x g for 3 
 61 
minutes. Once again the aqueous layer was transferred to a fresh tube and 2.5X 
the volume of 25:1 ethanol acetate acetate added, mixed by inversion, and placed 
at -70°C for 20 minutes. The mixture was then microfuged at 13 000 x g for 10 
minutes, the supernatant aspirated, and the pellet resuspended in 500 µl of 70% 
ethanol. The DNA was once again pelleted by microfugation for 10 minutes at 13 
000 x g at 4°C, and the supernatant aspirated. The pellet was allowed to dry at 55 
°C for 10 minutes and then resuspended in 80-150 µl of ddH2O depending on the 
size of the pellet.  
 
2.12 Polymerase Chain Reaction (PCR) 
 
Confirmation of 5´ RACE and cloning was determined by PCR on recombinant 
plasmid DNA obtained from miniprep, and/or colony PCR on the transformed 
cells. 0.6 µM of the GeneRacerTM 5´ and 5´ nested primers as well as 1 µM of the 
RF tail and RF tail internal primers were used. The reaction mixture consisted of 
standard PCR reagents: 2 mM MgCl2, 0.2 mM dNTP mix, 1X PCR reaction 
buffer, and 5 U Taq polymerase. Approximately 1 µg of DNA or a single colony 
of transformed cells was used as the template in the PCR reactions. PCR cycling 
conditions started with denaturation at 94ºC for 5 minutes. This was followed by 
25 cycles of 94ºC for 30 seconds, 58ºC for 30 seconds, and 72ºC for 1 minute. 
PCR ended with a final extension of 72ºC for 7 minutes. The PCR product was 
subjected to agarose gel electrophoresis to separate the amplified product from the 
reaction mixture and visualize results.   
 
PCR was also used to amplify the DCM of SNAMA that would later be expressed 
into recombinant protein. The reaction mixture and cycling conditions for the 
reaction were the same as mentioned above. However, 1 µM of the DWNN 
forward and RF reverse primers were used with 1 µg of pOT2 vector as the 
template. The pOT2 vector, 1665 bp in size, was obtained from the Flybase EST 
programme (accession AAF47162) and contains the entire SNAMA cDNA 
sequence.    
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2.13 Quantification of Nucleic Acid 
 
Nucleic acid concentration was determined by spectroscopy. First, the 
spectrophotometer was calibrated with deionised water in a quartz cuvette. 
Thereafter, the absorbance of the prepared samples was taken at 260 nm (A260) 
and 280 nm (A280). The nucleic acid samples were prepared by diluting the RNA 
or DNA by a factor of 100 with ddH2O. The samples were then placed in a quartz 
cuvette and the absorbance readings taken. The concentration was determined 
using the A260 reading, the dilution factor, and the optical density (OD) constant 
(A260 of 1 = 50 µg/ml for double-stranded DNA and 40 µg/ml for RNA). The 
purity of the DNA sample was determined using the A260/A280 ratio, where a value 
greater than 1.8 indicated that the sample had little protein contamination and was 
thus of high purity. 
 
2.14 Restriction Digestion of DNA  
 
In order to confirm that the 5´ -RACE and SNAMA PCR products had been 
successfully cloned into the multiple cloning site (MCS) of the cloning vector, 
restriction digestion on the recombinant vectors were performed. The vectors 
were restricted with EcoRI, as it has recognition sites that flank the MCS of the 
cloning vectors. Reaction conditions followed those recommended by the 
manufacturer of the restriction enzyme. All reactions were incubated at 37ºC 
overnight and stopped by the addition of 1X DNA loading dye the next morning. 
The success of the digestion was then determined by agarose gel electrophoresis.     
 
2.15 SDS-PAGE 
 
SDS-PAGE (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) is a 
technique that allows one to separate and visualize polypeptides in a gel matrix 
under denaturing conditions, thus allowing for qualitative analysis of protein 
(Laemmli, 1970). A discontinuous SDS-PAGE procedure was used with a 4% 
polyacrylamide stacking gel and 12% polyacrylamide separating gel. Protein 
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samples were suspended in 1X sample buffer, mixed, and boiled for 5 minutes 
before being loaded into the wells of the stacking gel. Electrophoresis was 
performed in 1X running buffer at a voltage of between 60 and 80 V. Proteins 
were visualized as bands in the gel by staining the gel with coomassie blue stain 
for 1 hour, followed by destaining overnight. If the protein sample could not be 
visualized with coomassie blue staining then the more sensitive silver staining 
technique was used as described by Morrissey (Morrissey, 1981). The size of the 
protein bands were then determined through visual comparison with the 
molecular weight marker.           
 
2.16 Recombinant Protein Expression in E. coli 
 
Protein expression in E. coli BL21(DE3)pLysS cells that have been transformed 
with the recombinant pET41(a) vector was induced by the addition of the 
galactose analog, isopropyl-β-D-thiogalactoside (IPTG). It was determined, 
through overexpression studies, that optimal expression of recombinant protein 
in these cells was achieved by induction with 0.2 mM IPTG for 4 hours at 37ºC. 
This provided the basis for the general procedure of recombinant protein 
expression in E. coli that was used during the course of this project. 
 
Starter cultures of transformed BL21(DE3)pLysS cells were incubated overnight 
at 37ºC with vigorous shaking. The following morning the starter culture was 
used to inoculate LB of between 50 and 500 ml, supplemented with 50 µg/ml 
kanamycin and 100 µg/ml chloramphenicol. The culture was then grown with 
vigorous shaking, at 37ºC, until the OD600 of the culture was between 0.4 and 
0.6. Recombinant protein expression was then induced by the addition of 0.2 
mM IPTG and allowed to express for 4 hours at 37ºC with vigorous shaking. 
The recombinant protein was then extracted from the BL21(DE3)pLysS cells. 
 
 
 
 
 64 
2.17 Recombinant Protein Extraction from E. coli 
 
BugBuster® protein extraction reagent was initially used for the extraction of 
recombinant protein from E. coli cells. However, due to the rate at which the 
BugBuster® reagent was being exhausted and because of financial concerns, a 
new lysis buffer was developed and a protocol designed for extraction of 
recombinant protein. The lysis buffer technique was far more economical with 
only a slight loss in amount and purity of protein when compared to extraction 
with BugBuster® reagent.  
 
2.17.1 Protein extraction using BugBuster reagent  
 
Recombinant protein extraction using the BugBuster® Extraction Reagent was 
accomplished by following the protocol provided by the manufacturer. SDS-
PAGE was then used to determine whether the recombinant protein was soluble 
(in the supernatant) or insoluble (in the pellet). If the recombinant protein was 
insoluble they formed aggregates known as inclusion bodies. Purification of 
inclusion body protein was then performed using the BugBuster® reagent and 
following the manufacturers protocol.   
 
2.17.2 Protein extraction using lysis buffer 
 
Bacterial cells containing expressed protein were harvested by centrifugation at 
5000 x g for 20 minutes. The cell paste was then resuspended in lysis buffer (5 
ml lysis bufffer/100 ml cell culture) and incubated at room temperature for 20 
minutes. The cell suspension was then sonicated for 3 cycles at 30 seconds each 
and then centrifuged at 16 000 x g for 20 minutes at 4ºC. Soluble protein present 
in the supernatant was retained and stored at –20ºC while insoluble inclusion 
body protein (pellet) was resuspended in the initial volume of lysis buffer and 
left at room temperature for 5 minutes. Three volumes of lysis buffer containing 
1% triton X-100 was then added to the suspension and rotated slowly for 20 
minutes at 4ºC. The inclusion body suspension was then centrifuged at 8 000 x g 
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for 15 minutes at 4ºC. The pellet was then washed with 2 volumes of lysis buffer 
with 1% triton X-100 and again centrifuged at 8 000 x g for 15 minutes at 4ºC. 
The pellet was then washed with one and a half volumes of lysis buffer that 
contained 1% triton X-100 and had been diluted 1:2 with distilled water. This 
was followed by a final centrifugation at 16 000 x g for 15 minutes at 4ºC. The 
inclusion body protein was then denatured to become soluble.               
 
2.18 iFOLDTM Protein Refolding System 1  
 
The iFOLDTM Protein Refolding System 1 is a simple, reliable, and 
comprehensive method to identify optimal protein refolding conditions. The 
system includes inclusion body purification reagents and a 96-well plate-based 
protein refolding buffer matrix (92 experimental and 4 control wells). By using 
the iFOLDTM Protein refolding system and following the manufacturers protocol 
the SNAMA inclusion body protein was denatured and rapidly diluted into the 
iFOLD 96-well buffer matrix. Absorbance readings at a wavelength of 340 nm 
were then taken for each of the 96 samples and recorded.     
 
2.19 Inclusion Body Solubilization 
 
Inclusion body protein was denatured and thereby solubilized using a urea based 
denaturation buffer and a procedure similar to that developed by Li and his 
colleagues (Li et al., 2004). 2 ml of denaturation buffer was added per gram of 
inclusion body protein. The mixture was then rotated at 4ºC overnight to allow 
for denaturation of the protein to occur. The following morning the mixture was 
centrifuged at 10 000 x g for 30 minutes to remove any debris. Solubilized 
protein was then analysed via SDS-PAGE.     
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2.20 Purification of Recombinant Protein  
 
2.20.1 His-tag purification 
 
Purification of recombinant protein that contained a histidine tag was achieved 
by nickel ion affinity chromatography using the HIS-SelectTM Nickel Affinity 
Gel from Sigma. Purification of soluble protein without denaturant was 
accomplished by following the manufacturer’s instructions provided. However, 
purification of protein under denaturing conditions followed a slightly different 
procedure to that supplied by the manufacturer of the affinity gel. 
 
His-tag purification under denaturing conditions 
 
Table 7. Buffers used during His-tag purification under denaturing conditions. 
All buffers were prepared fresh on the day of the procedure. 
 
Buffer Composition 
Equilibration buffer 0.1 M sodium phosphate buffer, pH 8.0; 8 M 
urea. 
Wash buffer 1 0.1 M sodium phosphate buffer, pH 6.3; 8 M 
urea. 
Wash buffer 2 0.1 M sodium phosphate buffer, pH 4.5; 8 M 
urea. 
Elution Buffer 50 mM sodium phosphate buffer, pH 8.0; 6 M 
Guanidine Hydrochloride. 
 
Between 1 and 2 ml of affinity gel was transferred to a chromotography column 
and allowed to settle for approximately 2 hours. The column was then washed 
with 2 volumes deionised water followed by equilibration with 3 volumes of 
equilibration buffer. Between 5 and 7 volumes of denatured recombinant protein 
was then added onto the column at a flow rate of 2 to 10 column volumes/hour. 
After all the sample had been loaded the column was washed with 5 volumes of 
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wash buffer 1. This was followed by an additional abnormal column wash with 3 
volumes of wash buffer 2. The histidine-containing sample was then eluted 
using 2 volumes of elution buffer. The column/affinity gel was then cleaned as 
described by the manufacturer and kept at 4ºC for future use.  
 
2.20.2 GST-Tag Purification 
 
The purification of recombinant protein containing a GST-tag was performed by 
glutathione affinity chromatography using glutathione agarose from Sigma. The 
procedure that was followed and buffers that were used are described in the 
product information manual supplied with the glutathione agarose. 
 
2.21 Dialysis  
 
Dialysis was performed to remove the denaturant, GuHCl, from purified 
recombinant protein thus refolding the recombinant protein. Pure recombinant 
protein was either added to SnakeSkinTM pleated dialysis tubing or Slide-A-
Lyzer® dialysis cassettes and set-up as described by the manufacturer. 
Approximately 5 ml of sample was then dialyzed against 500 ml of dialysis 
buffer overnight at 4ºC. The following morning the sample was centrifuged at 10 
000 x g for 30 minutes at 4ºC to remove any protein that might have precipitated 
out of solution. The dialysis buffer that was used for buffer exchange prior to 
CD spectroscopy differed from the norm as it lacked cyclodextrin, arginine, and 
EDTA, which interfered with the spectrophotometer readings at lower 
wavelengths. 
 
2.22 Quantification of Protein 
 
The concentration of an unknown protein was determined by the Bradford 
method, using a standard curve that was constructed from bovine serum albumin 
(BSA) standards and Bio-Rad Protein Assay. A BSA standard curve, ranging 
from 20-140 µg of protein (0.2-1.4 µg/µl), was constructed and stored in the UV-
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160A UV-visible spectrophotometer. The protein samples were prepared in the 
same way as the standards by diluting the protein 100X with 1X Bio-Rad protein 
assay reagent and incubating for 30 minutes at room temperature.  1X Bio-Rad 
assay reagent was used to calibrate the spectrophotometer at A595 before the 
readings of the protein samples were taken. The concentration of the protein (in 
µg/ml) was then calculated automatically by the spectrophotometer using the 
BSA standard curve previously programmed. Protein was concentrated to 
required amounts using the Stirred Ultrfiltration Cell and following the 
manufactirer’s instructions.    
 
2.23 Circular Dichroism (CD) Spectroscopy  
 
Circular dichroism (CD) spectroscopy is a valuable tool for the characetrization 
of protein structures in solution due to the inherent information content of the far 
UV CD spectra between 180 and 250 nm (Böhm et al., 2002). CD spectroscopy 
was used in order to gain important information concerning the secondary 
structure of the pure, recombinant GST-SNAMA fusion protein following 
dialysis in the absence of cyclodextrin, arginine and EDTA. Approximately 2.8 
µM (~ 0.2 µg/µl) of GST-SNAMA fusion protein in 50 mM sodium phosphate 
buffer and 2.8 µM GST protein in 50 mM sodium phosphate buffer was used 
during the analysis. 50 mM sodium phosphate buffer was used as a blank for the 
GST-SNAMA and GST proteins. The GST protein without SNAMA was used 
both as a control to determine the accuracy of the procedure as well as a blank 
for the GST-SNAMA fusion protein. Circular dichroism spectra were recorded 
in the range from 190 to 250 nm at an interval of 0.5 nm with a Jasco J-810 
Spectropolarimeter. Five scans were averaged for the sodium phosphate blank 
and ten scans averaged for each of the GST-SNAMA and GST proteins to obtain 
one spectrum for each sample. The CD spectra for each of the samples were then 
compared to known secondary structure spectra (Andrade et al., 2003; Bondesen 
and Schuh, 2001; Kelly and Price, 2000) in order to accurately predict the 
secondary structure of SNAMA.                   
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2.24 Ubiquitin Conjugation Assay 
 
An ubiquitin conjugation assay was performed in order to determine whether the 
recombinant SNAMA protein exhibited ubiquitin ligase activity. To determine 
the E2 that SNAMA would have optimal activity with, a series of E2s (UbcH2, 
UbcH3, UbcH5a, UbcH5b, UbcH5c, UbcH6, UbcH7, UbcH10) were initially 
used. The assay reaction mixture consisted of 7.2 µg ubiquitin, 0.1 µg E1, 0.4 µg 
E2, 4.6 µg GST-SNAMA fusion protein (E3), 2 mM DTT, 2 mM ATP, 5 mM 
MgCl2, 250 µM ZnCl2, and made up to 30 µl with 50 mM sodium phosphate 
buffer, pH 8.0. The reaction mixture was then incubated at 30ºC for 2 hours and 
stopped by the addition of sample buffer. To check for ubiquitin ligase activity 
the reaction mixture was run on an SDS-PAGE gel. Ubiquitin conjugation 
assays in the absence of the key components of the ubiquitin system, namely the 
E1, E2, E3, ubiquitin, ATP, and ZnCl2, were performed as controls.  
 
2.25 Bioinformatic tools 
 
Gene-specific primers were designed using Gene Runner (Version 3.05). 
Chromatograms of sequenced DNA obtained from Inqaba Biotech were 
visualized using Chromas (Vesion 1.45). Sequence alignments of both protein 
and DNA were carried out using DNAMAN version 4.03 (Lynnon Biosoft, 
Quebec, Canada) and ClustalX, using the optimal alignment setting. Secondary 
structure prediction for the DCM of SNAMA was achieved using the PSIPRED 
program version 2.5 (Bryson et al., 2005).  
 
Table 8. Web addresses for various bioinformatic tools. 
 
Bioinformatic Tool Web Address 
BLAST http://www.ncbi.nlm.nih.gov/BLAST 
Chromas http://www.technelysium.com.au/chromas.html 
ClustalX http://www-igbmc.u-
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strasbg.fr/BioInfo/ClustalX/Top.html. 
FlyBase http://flybase.bio.indiana.edu  
PSIPRED http://bioinf.cs.ucl.ac.uk/psipred 
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3. TRANSCRIPTIONAL REGULATION OF SNAMA   
 
The human RbBP6 homologue of SNAMA is expressed as three transcripts of 
6.1, 6.0, and 1.1 kb (Pugh et al., 2006). These transcripts give rise to proteins of 
1792, 1758, and 118 amino acids, designated RbBP6 isoforms 1, 2, and 3 
respectively. The fact that human RbBP6 has various isoforms suggests that 
there might be additional isoforms of the SNAMA protein. Alternative splicing, 
poly-adenylation, or the presence of an internal promoter region and 
transcriptional start site within a gene would lead to the expression of isoforms. 
Internal promoters are usually present in more advanced and complex organisms 
where regulation of gene expression is intricate and under tight control (Neuman 
et al., 2005). These downstream internal promoters usually reside in the first 
introns, which are on average longer than other introns and are, sometimes, 
exceptionally long (Kriventseva and Gelfand, 1999). The annotated structure of 
Drosophila genes from chromosome 2R (where SNAMA is found) shows that 
more than 50% of the genes larger than 30 Kb contain large 5´ introns, and two 
or more predicted remote first exons regulated by alternative promoters 
(Neuman et al., 2005).   
 
Determining the transcriptional start site of a gene makes it possible to examine 
the regulatory regions that define the promoter region and thereby gain further 
insight into how expression of protein is controlled. It is believed that during the 
course of evolution the sequences for promoter regulation have been preserved 
in the promoter region and that their occurrence frequencies are far from random 
(Gershenzon et al., 2006). There are six core promoter elements that have been 
discovered in eukaryotes thus far. These elements are TATA box, Initiator (Inr), 
Downstream Promoter Element (DPE), TFIIB recognition element (BRE), 
Downstream Core Element (DCE), and Motif Ten Element (MTE) (Smale and 
Kadonaga, 2003; Lim et al., 2004; Lewis et al., 2000). Four of these core 
promoter elements have been experimentally identified in Drosophila promoters: 
the TATA box, Inr, DPE and MTE (Smale and Kadonaga, 2003; Lim et al., 
2004). Comparison between human and Drosophila shows consistent 
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percentages of promoters with TATA, Inr, DPE, and synergetic combinations 
thereof, as well as most of the same functional and mutual positions of the core 
elements (Gershenson et al., 2006).       
 
The transcriptional initiation site of a gene can be determined by examining the 
5´ -terminus of a transcript through the 5´ rapid amplification of cDNA ends (5´ 
RACE) technique (Bensing et al., 1996; Argaman et al., 2001; Gum et al., 2003; 
Aspegren et al., 2004). Analysis of the 5´ region of the SNAMA transcript was 
determined using the GeneRacerTM 5´ RACE, which amplifies the beginning of 
the transcript to a point where the RF Tail primer binds. In this way it is possible 
to identify the core promoter elements that define the promoter region/s of 
SNAMA, thus providing valuable information into the transcriptional regulation 
of the gene.    
 
3.1 5´ Rapid Amplification of cDNA Ends (5´ RACE) 
 
5´ RACE using RNA from Drosophila embryos and the GeneRacerTM (GR) kit 
resulted in the amplification of two distinct DNA fragments of varying size 
(Figure 10; see also Figure 12 for primer positions). The smaller fragment 
ranged from 650-700 bp while the larger ranged from 800-850 bp, depending on 
the combination of primers used. The DNA fragment between 800 and 850 bp in 
size was expected as the RF Tail primer that was used during reverse 
transcription was designed to bind at the end of the RFL motif (Appendix I). The 
presence of the DNA fragment from between 650 and 700 bp in size appeared to 
indicate that there was an additional promoter region and transcriptional start 
site, downstream the initial transcriptional start site. This sparked much interest 
as it would imply that there was an internal promoter in the SNAMA gene.  
  
The slight variation in sizes between each of the two distinct 5´ RACE products 
can be attributed to the combination of primers that were used during 
GeneRacerTM PCR.  Amplification of the SNAMA cDNA resulted in fragments 
that were slightly smaller when using the GR 5´ Nested primer than when using 
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the GR 5´ primer. This was expected due to the GR 5´ Nested primer binding the 
GR oligo downstream the position where the GR 5´ primer binds. Similarly, 
amplification with the RF Tail Internal reverse primer resulted in slightly smaller 
fragments than that amplified using the RF Tail primer. This was due to the RF 
Tail Internal primer binding SNAMA upstream the RF Tail primer. 
Interestingly, the smaller DNA fragment was far more prominent when the RF 
Tail was used as the reverse primer. When the RF Tail Internal primer was used 
the smaller band was barely visible in the gel. In contrast, the larger DNA 
fragment was far more prominent when the RF Tail Internal primer was used as 
the reverse primer.      
  
 
 
Figure 10. 5´ Rapid amplification of cDNA ends using Drosophila RNA. Two 
distinct fragments of different size were amplified when 5´ RACE was 
performed on Drosophila RNA from adults. The smaller fragment was between 
650 and 700 bp in size while the larger was between 800 and 850 bp. Different 
combinations of primers resulted in slight variations in DNA fragment size and 
band intensities. A positive control using HeLa RNA and the Control B.1 primer 
resulted in the amplification of a fragment approximately 900 bp in size as 
expected (lanes 5 and 6).   
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5´ RACE using HeLa control RNA as a template resulted in the amplification of 
a DNA fragment approximately 900 bp in size when using the Control B.1 
reverse primer together with the GR primers (Figure 10). This was the expected 
size for the 5´ RACE product of HeLa (according to manufacturer), thus 
confirming that 5´ RACE had occurred successfully.       
 
3.2 Cloning of 5´ RACE Products 
 
To confirm that the two DNA fragments were amplified from the SNAMA gene 
and determine the exact site of transcription initiation, they were both cloned and 
sequenced. The 800-850 bp fragment, that results from amplification with the 
GR 5´ and RF Tail Internal primers, was used when cloning the larger of the two 
5´ RACE products. This fragment was used as it contained the most DNA when 
compared to the other 800-850 bp fragments, as is evident by its greater band 
intensity in the gel (Figure 10). For the same reason the 650-700 bp fragment 
that results from amplification with GR’ Nested and RF Tail primers was used 
when cloning the smaller of the two 5´ RACE products. 
 
The two DNA fragments were excised from the gel, ligated into TA cloning 
vectors and cloned for sequencing. Colony PCR was performed in order to 
confirm successful cloning and ensure DNA fragment sizes (Figure 11). The RF 
Tail was used as the reverse primer when amplifying the 650-700 bp DNA 
fragment, as this primer was most effective during initial amplification of the 
cDNA. For the same reason the RF Tail Internal primer was used during the 
amplification of the larger 800-850 bp fragment. As with 5´ RACE, a somewhat 
smaller fragment is amplified when using the GR 5´ Nested primer compared 
with the GR 5´ primer due to different positions at which the primers bind the 
product.     
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Figure 11. PCR amplification to verify cloning of 5´ RACE products. The 650-
700 bp fragment was amplified using the RF Tail reverse primer (lane 1), in 
contrast to the 800-850 bp fragment, which was amplified using the RF Tail 
Internal primer (lanes 2 and 3). 
 
3.3 Sequence Alignments of the 5´ RACE Clones 
 
The two clones containing the products from 5´ RACE were sent to Inqaba 
Biotec for sequencing. The sequences for each of the clones were aligned with 
themselves, the GR oligo, the SNAMA cDNA sequence, and the primers, to 
ascertain whether the fragments were amplified from the SNAMA gene and 
determine where transcription begins (Figure 12). Alignment showed that the 
800-850 bp clone was in fact 790 nucleotides in length and aligned completely 
with SNAMA cDNA, as did the RF Tail primer used during amplification (Figure 
12 (b)). The transcriptional start site of the 790 bp fragment (GCATC) is 
indicated at the point where the GR oligo ends. 
 
The 650-700 bp clone was shown to be 681 nucleotides in length and did not 
align significantly with SNAMA, yet the RF Tail primer showed complete 
binding to the amplified fragment (Figure 12 (a)). This was unfortunate as it 
suggested that this fragment was not amplified from SNAMA but rather from 
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Figure 12. Multiple sequence alignment of cloned 5´  RACE products. (A) 
Alignment of the 650-700 bp clone shows a fragment 681 bp in size that does 
not have a significant alignment with the SNAMA sequence. In contrast, the 
alignment shows that the RF Tail primer binds completely to the fragment. (B) 
Alignment of the 800-850 bp clone shows a fragment of 790 bp that aligns 
completely with SNAMA and the RF Tail primer. 
 77 
another gene within Drosophila. This was confirmed by BlastN searches against 
the Drosophila genome, which showed significant alignment of the 681 bp 
fragment with a gene approximately 4.6 Mbp upstream of SNAMA, in the right 
arm of chromosome 2 of Drosophila (ref: NT 033778) (Appendix II). This 
fragment was amplified during 5´ RACE due to the sequence of the reverse 
primer (RF Tail) that was used during reverse transcription of the Drosophila 
embryonic RNA. The first half of this primer shows complete homology to the 
gene identified upstream of SNAMA. Thus, the primer would have recognized 
and bound both the SNAMA gene and the gene upstream, which were both then 
reverse transcribed into the cDNA and later amplified. This also accounts for the 
virtual absence of a 650-700 fragment when 5´ RACE was performed using the 
RF Tail Internal primer (Figure 10), as this primer did not have homology to the 
other gene within the Drosophila genome.      
 
 
Figure 13. The 5´ region of the SNAMA gene that is ultimately translated into 
the DWNN catalytic module. The GeneRacerTM (GR) oligo along with primers 
used during transcriptional start site determination are also shown. 
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It is evident that SNAMA contains a single transcriptional start site at the 5´ 
region of the gene. A summary of these results is illustrated in Figure 13, which 
indicates the 5´ region of SNAMA and its translation into the DWNN domain and 
RFL motif that comprise the DCM. Also shown are the primers used in 
determining the transcription start site of SNAMA.  
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4. DOES SNAMA EXHIBIT UBIQUITIN LIGASE ACTIVITY? 
 
The modification of proteins by ubiquitin is essential for numerous cellular 
processes. For example, ubiquitin-dependent protein degradation is involved in 
the regulation of apoptosis, cell cycle progression, signal transduction, 
transcription, DNA repair, and protein quality control (Laney and Hochstrasser, 
1999). Ubiquitination begins with the activation of ubiquitin by E1 in an ATP-
dependent manner, resulting in the covalent attachment of ubiquitin to the E1 
(Haas and Rose, 1982). Ubiquitin is subsequently transferred to an E2. Finally, 
the E3 attaches ubiquitin to its substrate by interacting with both the E2 and 
target protein (Hershko and Ciechanover, 1998).  
 
The most common of the E3 ligases, the RING finger E3s, are dependent on 
their RING finger conformation for their ubiquitin ligase activity. The U-Box 
and PHD are referred to as derivatives of the RING finger E3 as they also form a 
RING finger conformation (Sun, 2003). However, these RING finger structures 
are stabilized in a different way to the characteristic RING finger. 
 
SNAMA is a member of the RbBP6 superfamily. All members of this family 
contain a highly conserved N-terminal region known as the DWNN Catalytic 
Module (DCM). The module is comprised of the DWNN domain, zinc finger 
motif and RFL motif respectively (Mather et al., 2005). The RFL motif of 
SNAMA includes the highly conserved cysteine residues present in 
characteristic RING fingers but differs from the standard by substitution of a 
histidine residue in the fourth ligand with a serine residue (Mather et al., 2005).  
 
The ability of a protein to exhibit ubiquitin ligase activity can be tested for by 
performing an ubiquitin conjugation assay using the protein as the E3 (Imai et 
al., 2003). A pure and active form of the protein is needed in order to perform 
this assay. The DCM of SNAMA was expressed as a recombinant protein in E. 
coli and formed insoluble inclusion body aggregates. The insoluble inclusion 
body protein was solubilized, purified and refolded into its native state. The pure 
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and active form of the recombinant SNAMA protein was then used as the E3 in 
an ubiquitin conjugation assay to determine whether it had ubiuqitin ligase 
activity. 
 
4.1 Recombinant Expression and Extraction of SNAMA  
 
The DCM of SNAMA was cloned and expressed in E. coli BL21(DE3)pLysS 
cells using the pET41(a) expression vector (Appendix VI). Optimal expression 
of recombinant protein in these cells was achieved through induction with 0.2 
mM IPTG for 4 hours at 37ºC. The recombinant GST-fusion protein, 
representing the DCM of SNAMA, was referred to as GST-SNAMA (GST-S). 
Expression of GST-S resulted in the protein forming insoluble inclusion body 
aggregates, approximately 70 kDa in size, in the pellet (Figure 14). Expression 
of a GST protein (GST), in cells transformed with intact pET41(a), was used as a 
positive control that resulted in an approximately 38 kDa soluble protein, present 
in the supernatant (Figure 14). Whole cells lacking the pET41(a) vector were 
used as a negative control. Working with inclusion bodies is challenging as you 
have to solubilize and purify the protein before attempting to refold it back into 
its native state to use in activity assays.  
 
The parameters under which protein expression occurs were changed in an 
attempt to solubilize the protein during expression. These parameters included 
induction temperature, protein expression time, and addition of zinc ions during 
expression. Protein expression was attempted at 30ºC, room temperature, and 
18ºC. Protein expression was also induced at various temperatures for 2 hours, 6 
hours, and overnight. Finally, expression of the protein was attempted in the 
presence of zinc ions. In all cases there was no affect on the solubility of the 
protein although levels of protein expression did fluctuate. The insoluble GST-S 
inclusion bodies were thus denatured using urea in order to solubilize the 
protein. 
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Figure 14. Recombinant expression of GST-fusion SNAMA protein. 
Recombinant protein was expressed in E. coli BL21(DE3)pLysS cells. GST-
SNAMA (GST-S) is expressed as insoluble inclusion body protein 
approximately 70 kDa in size (lane 2). The GST protein (GST) is expressed as a 
38 kDa soluble protein (lane 3). Protein extracted from the E. coli whole cell, 
lacking the pET41(a) vector, is used as a negative control (lanes 5 and 6).   
 
4.2 His-Tag Purification of Denatured Recombinant SNAMA  
 
The denatured, recombinant SNAMA protein was not very pure and was present 
amongst contaminating protein that included denatured membrane bound protein 
from E. coli (Figure 15). This could hinder both the refolding and activity of 
SNAMA and thus the recombinant protein was purified from the contaminating 
protein. Initially, glutathione agarose was used in an attempt to purify the GST-S 
through its affinity to the GST tag fused to SNAMA. However, this proved 
unsuccessful as GST-S was in its unfolded, denatured state and the glutathione 
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could therefore not recognize and bind the GST tag. Nickel charged agarose was 
then used in an attempt to purify the recombinant SNAMA protein through its 
affinity to the His6 tag that is associated with the recombinant protein. Nickel ion 
affinity chromatography is capable of purifying His tag containing proteins in 
both the unfolded (denatured) and folded (native) states. In fact, purification of 
the protein is often more effective when it is its denatured state as the hexa-
histidine residues are more exposed.      
 
 
Figure 15. His-tag purification of denatured recombinant SNAMA protein. 
Denatured SNAMA protein was present amongst contaminating protein (lane 1). 
Ni+2 affinity chromatography under denaturing conditions was performed as 
described in the manufacturers protocol. Pure GST-SNAMA fusion protein was 
unexpectedly eluted using GuHCl (lane 6) rather than elution buffer in the step 
before (lanes 4 and 5). Note that the GST-SNAMA fusion protein appears 
smaller in size due to the gel being scewed.   
 
Ni+2 affinity chromatography was used to purify the recombinant SNAMA 
protein under denaturing conditions. Results showed that there was specific 
binding of SNAMA to the affinity column, as was evident by very little 
recombinant protein eluted during the first washes (Figure 15). Unexpectedly, 
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recombinant SNAMA was not eluted during the typical, initial elution wash 
(wash buffer 2 in section 2.20.1). Instead, the recombinant SNAMA protein was 
eluted with buffer containing GuHCl as an extremely pure protein (Figure 15). 
Other than a denaturant, GuHCl is also commonly used to remove protein from 
the Ni+2 agarose during the cleaning process of the column. The GST-SNAMA 
fusion protein appears smaller in size when compared to the denatured SNAMA 
protein. This was due to the gel being placed at a slightly scew angel prior to its 
image being capured.    
 
The imidazole ring present in the side chain of the histidine residues, contains a 
pKa of 6.04 and, is ultimately responsible for its affinity to the metal ions in the 
agarose. In buffers with a pH value greater than 6.04 the imidazole rings will be 
charged and thus bind specifically to the Ni+2 charged affinity gel. Normally, the 
elution buffer removes bound protein due to a drop in pH of the buffer to 4.5. 
This causes the imidazole rings of histidine residues to lose their charge as they 
become protonated and thus lose the ability to bind Ni ions in the affinity 
column. However, this drop in pH does not affect the binding of the recombinant 
SNAMA to the affinity column suggesting that the imidazole rings remain in 
their anionic state. Instead the bound protein is eluted with GuHCl. This is 
probably due to the presence of guanidinium cations (Gdm+) in solution that 
bind with greater affinity to the imidazole rings of the histidine residues than the 
nickel ions, thus allowing for their elution from the column. 
   
4.3 Optimal Refolding Conditions for SNAMA 
 
Defining conditions that promote refolding of the denatured protein into its 
native conformation is empirical, difficult and time-consuming. To overcome 
these problems, the iFOLDTM Protein Refolding System 1, together with the 
literature (Clark, 1998; Li et al., 2004; Karuppiah and Sharma, 1995; Chen et al., 
2005; Cabrita and Bottomley, 2004), was used to determine the optimal 
refolding conditions for the recombinant SNAMA protein. Absorbance readings 
at 340 nm were recorded for 96 samples following the rapid dilution of SNAMA 
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protein into 96 different refolding buffers (Figure 16). The composition for each 
of the buffers within the 96-well plate can be seen in Appendix III. The lower 
the A340 value of the sample the more effective the refolding buffer as the 
absorbance of the solution is an indication of the degree of precipitation of 
protein out of solution. The composition of the top ten buffers with lowest 
absorbance were then examined to determine the best composition of additives 
for refolding recombinant SNAMA protein (Table 9).  
 
 
Figure 16. Refolding conditions for the recombinant SNAMA protein. GST-S 
protein was refolded by rapid dilution of the denatured protein into the 96-well 
iFOLD plate (Appendix III). The relative absorbance of samples was taken at 
340 nm with the ten most effective refolding buffers indicated by an asterisk.     
 
The iFOLDTM protein refolding system showed that refolding buffers with a pH 
of 8 were the most effective when refolding SNAMA (Figure 16). SNAMA is 
most stable at this pH as precipitation levels of the protein remain low on a 
regular basis across various refolding buffers. This is illustrated by the high 
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consistency of low peaks (A340 < 0.12) at this pH. In addition, majority of the top 
ranked refolding buffers for SNAMA had this pH (Table 9). Other buffers with a 
pH of 7 and/or 7.5 appear to be effective refolding buffers. However, these 
buffers do not refold SNAMA with the same consistency as a buffer with a pH 
of 8 and SNAMA is not as stable throughout a broad range of buffers. 
Furthermore, the effeciveness of the buffers with a pH of 7 and 7.5 is most likely 
due to the refolding components within the buffer.    
 
Cyclodextrin is by far the most successful refolding additive of SNAMA as it 
appeared most frequently in the best refolding buffers for SNAMA. This is not 
surprising as cyclodextrin is both a stripping agent, used for the removal of 
detergents (Rozema and Gellman, 1995), and a suppressing agent, preventing 
aggregation of protein during refolding (Karuppiah and Sharma, 1995).  
 
Independently, the L-arginine and buffer solutions alone were successful in 
causing SNAMA to refold well (Table 9). L-arginine is mentioned in a great deal 
of published literature involving protein refolding (Arakawa and Tsumoto, 2003; 
Bell et al., 2002). Arginine plays an important role by not facilitating the actual 
refolding of the protein but rather suppresses aggregation of the protein during 
refolding. Additives that facilitate disulphide bond formation include 
combinations of reduced and oxidized forms of glutathione (GSG/GSSG), 
cysteine and cystine, or DTT/oxidized glutathione. These redox systems are 
usually added to accelerate shuffling of disulphide bonds. However, they are not 
pivotal as air is also suitable to promote disulphide bond formation through air 
oxidation (Cabrita and Bottomley, 2004). Furthermore, “shuffling” of disulphide 
bonds is generally catalyzed by trace amounts of metal ions and also by slightly 
alkaline pH of between 8 and 9. Conversely, EDTA was added to the refolding 
buffer to scavenge unwanted metal ions, which could cause oxidation reactions. 
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Table 9. The most effective refolding buffers for recombinant SNAMA. The composition of the top ten refolding buffers for 
SNAMA when using the iFOLD Refolding Protein System 1 were compared. Cyclodextrin appeared most frequently while 100 
mM NaCl, L-arginine and EDTA appear to be amongst the most significant of the additives.     
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4.4 Refolding the Pure, Denatured SNAMA  
 
A pure form of the recombinant SNAMA protein was acquired in its denatured 
form and needed to be refolded into its native state. Dialysis of the His-tag 
purified SNAMA protein was performed to slowly remove GuHCl from the 
sample through buffer exchange with the dialysis (refolding) buffer, thus 
refolding SNAMA. Many dialysis buffers were designed using the information 
obtained from the iFOLDTM Protein Refolding System 1 combined with 
information gathered from literature (Clark, 1998; Li et al., 2004; Karuppiah and 
Sharma, 1995; Chen et al., 2005; Cabrita and Bottomley, 2004). Most buffers 
that were tried caused precipitation of the SNAMA protein out of solution. This 
was determined confirmed through visualization of the protein in the 
polyacrylamide gel and through spectrophotometric quantification. However, 
after much trial and error it was ultimately discovered that denatured SNAMA 
protein could be successfully refolded by dialysis against a phosphate-based 
refolding buffer of pH 8.0, containing cyclodextrin, L-arginine, NaCl and 
EDTA. This resulted in only a slight precipitation of recombinant SNAMA with 
majority of the protein remaining in a soluble, refolded form (Figure 17). 
Refolding took place at 4ºC as this temperature minimizes protein aggregation 
best.  
 
4.5 Confirmation of Correctly Refolded SNAMA Protein  
 
Once refolded, it had to be determined whether GST-S had refolded correctly 
into its native conformation or misfolded into a non-active form. This was 
confirmed through affinity binding and secondary structure determination of the 
recombinant protein. Binding of GST-S to the glutathione agarose column and 
elution from the column with reduced glutathione illustrated that the GST tag of 
the recombinant protein had specificity for the glutathione (Figure 18). This 
confirms that the GST portion of the recombinant protein refolded into its native 
state, which is shown by its ability to recognize and bind glutathione. However, 
this does not prove that the SNAMA fraction of the recombinant protein has 
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refolded correctly but suggests that it could have due to the GST portion having 
refolded correctly. 
 
 
Figure 17. Dialysis of His-tag purified SNAMA protein. The His-tag purified 
SNAMA sample before dialysis can be seen in lane 1. Following dialysis the 
now refolded SNAMA sample shows a slight decrease in amount of protein, 
which was confirmed by spectrophotometric quantification (lane 2). Denatured 
inclusion bodies (IBs) prior to purification and dialysis can be seen in lane 3.  
 
Circular dichroism (CD) spectroscopy was used to determine the secondary 
structure of the recombinant SNAMA protein by far UV CD spectra (between 
190 and 250 nm). Initially poor readings were obtained due to the buffer 
components of the sample interfering with the absorbance of light by the protein 
at the lower, more significant wavelengths. These components within the buffer 
included sodium phosphate buffer concentration, cyclodextrin, L-arginine and 
EDTA. Dialysis in the absence of cyclodextrin, L-arginine and EDTA was 
therefore attempted and proved successful, but at a price. Large amounts of 
protein was lost during the dialysis due to absence of the refolding agents, and 
thus protein was concentrated in order to obtain the large amounts that were 
needed in order to perform CD spectroscopy.  
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Figure 18. Glutathione affinity chromatography of refolded GST-S protein. The 
GST-S protein was eluted during the elution wash using glutathione (lane 3), 
with no protein present in the flow through wash (lane 1). The dialyzed GST-S 
protein sample prior to loading onto the glutathione agarose column can be seen 
in lane 2.  
  
The fact that there were CD spectra for both the refolded GST-S protein sample 
and the GST protein proved that the protein had a secondary structure and that 
refolding had occurred (Figure 19). A CD spectrum with no troughs or peaks 
(zero absorbance) was obtained for the denatured GST-S protein sample, 
indicating that there was no secondary structure (results not shown). This is what 
was expected from a non-folded protein. The CD spectra for each of the samples 
was then compared to typical secondary structures defined in literature in order 
to determine the secondary structure for the DCM of the SNAMA protein (Kelly 
and Price, 2000) (Appendix VII).   
  
The GST protein was used both as a positive control and a blank during CD 
spectroscopy studies. As a positive control it portrayed the characteristic α-
helical spectrum having a trough between 200 and 240 nm with lows at 220 nm 
and 210nm, and a slight peak between them. Furthermore, the spectrum 
increased to an immense peak at 190 nm much like classical α-helical proteins. 
This was expected as GST is predominantly an α-helical protein. The GST 
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protein was also used as a blank against the GST-SNAMA protein to eliminate 
the effect of the GST tag secondary structure from the secondary structure 
determination of SNAMA.   
 
The CD spectrum for the GST-SNAMA protein was very similar to that of the 
GST protein as it represented a protein that was predominantly α-helical. 
However, the GST-SNAMA spectrum was different in that it showed a large 
trough just below 200 nm that is indicative of a protein containing random coils. 
The spectrum for only the DCM of SNAMA (GST-S – GST) was very different 
to that observed when including the GST tag as it lost all of its α-helical 
characteristics. On the contrary, the spectrum was indicative of a protein that is 
made up mostly of β-turns, random coils and β-sheets. The presence of β-turns is 
represented by a slight trough between 220 nm and 230 nm, a peak at 
approximately 202 nm, and a trough at 190 nm (Figure 19). Random coils are 
represented by a major low at 198 nm while the presence of β-sheets is 
represented by a slight peak at 196 nm.  
    
The secondary structure determined for the DCM of SNAMA by CD 
spectroscopy is similar to that predicted by bioinformatic analysis and the 
literature (Appendix IV). The DWNN domain is expected to contain three and a 
half α-helices, five β-sheet strands and seven reverse turns (Pugh et al., 2006). 
The zinc finger knuckle usually has two short β-strands followed by a short α-
helix and connected by a turn (Krishna et al., 2003). The RING finger motif is 
usually made up of three β-strands, a α-helix and long loops. The secondary 
structure predicted using the PSIPRED bioinformatic program was very similar 
for these domains within the DCM. Overall, the predicted secondary structure 
for SNAMA showed a protein that consisted predominantly of random coils and 
turns with a greater presence of β-sheets than α-helices. This data is similar to 
that acquired from CD spectroscopy and thus it was concluded that the protein 
had refolded into its native conformation. This would ultimately be confirmed 
by testing for the activity of the pure refolded protein in an activity assay.   
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Figure 19. CD spectra for the recombinant GST-S and GST proteins. The yellow spectrum (square) represents the GST protein blanked 
against its buffer and is predominantly α-helical with a trough between 200 nm and 240 nm, lows at ~ 220 nm and 210 nm with a slight 
peak between them, and a large peak at 190 nm. The blue spectrum (diamond) represents the GST-S sample blanked against its buffer 
also shows α-helical characteristics with a trough between 202 nm and 240 nm, and peaking around 190 nm. However, this spectrum 
also indicates the presence of random coils by the large trough at ~ 200 nm. The red spectrum (circle) represents the GST-S sample 
blanked against the GST-protein and is indicative of β-turns, random coils, as shown by a slight trough between 220 nm and 230 nm, a 
peak at ~ 202 nm, a major low at ~ 198 nm, a peak at ~ 196 nm, and a trough at 190 nm.                        
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4.6 Ubiquitin Conjugation Assays Using SNAMA as the E3 
 
The pure and correctly folded recombinant SNAMA protein was used as the 
ubiquitin ligase (E3) in an ubiquitin conjugation assay to ascertain whether the 
protein has ubiquitin ligase activity. Initially the assay was performed with a set 
of various ubiquitin conjugation enzymes (E2s) to determine which of the E2s 
would function best with SNAMA as an E3. The key components of the 
ubiquitination process were then examined by performing conjugation assays in 
the absence of an E1, E2, E3, ubiquitin, ZnCl2, and ATP. 
 
4.6.1 Specificity of SNAMA E3 activity to various E2s 
 
SNAMA ubiquitin ligase activity was initially determined using refolded GST-S 
as the E3 and 8 different E2s in an ubiquitin conjugation assay (Figure 20). 
Recombinant SNAMA (E3) is visible as an approximately 70 kDa protein, with 
a ~ 23 kDa protein contaminant also visible in the sample. The various E2s that 
were used are marked with an asterisk while the ubiquitin activating enzyme 
(E1) is visible as an approximately 140 kDa protein. Ubiquitin is visible at 
approximately 35 kDa with a slightly smaller peptide of ~ 25 kDa also visible in 
the sample.  
 
The ubiquitin conjugation assays led to the ubiquitination of the SNAMA 
protein itself through a process known as autoubiquitination. This was evident 
by the formation of “smears” in the SDS-PAGE gel that indicate various degrees 
of poly-ubiquitinated SNAMA protein (Figure 20). The smears depicting 
ubiquitinated protein began at 100 kDa and increased in size according to the 
degree of poly-ubiqutination. Majority of ubiquitinated protein appeared to be 
greater than 170 kDa in size, illustrated by intense smears in the gel representing 
a number of different sized proteins (Figure 20). This was expected as SNAMA 
alone was 70 kDa in size while the ubiquitin molecules, which were fused to 
GST, were each approximately 30 kDa in size. Thus, a poly-ubiqutinated 
SNAMA protein tagged with only 3 or 4 ubiquitin molecules would already 
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Figure 20. The test for ubiquitin ligase activity of SNAMA, and its specificity towards various E2s. Ubiquitin conjugation assays 
were performed using recombinant SNAMA as the E3 (~ 70 kDa) with 8 different E2s (marked with an asterisk). Ubiquitin and E1 
are visible as approximately 35 kDa and 140 kDa peptides respectively. “Smears” representing multiple polypeptides as a result of 
polyubiquitination are seen getting larger from approximately 100 kDa. SNAMA catalyses the ubiquitination of itself 
(autoubiquitination), illustrated by majority of the polypeptides being larger than 170 kDa in size. Ubiquitination occurs optimally 
with UbcH5 E2s, in particular UbcH5a.   
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have molecular weights of 160 kDa and 190 kDa respectively. It is therefore easy 
to see that there would be many poly-ubiquitinated SNAMA protein larger than 
170 kDa in size as was represented by the smear.      
 
Recombinant SNAMA E3 had activity in the presence of a number of E2s, which 
include UbcH2, UbcH3, UbcH5 and UbcH6. However, SNAMA E3 had the 
greatest specificity for the UbcH5 family of E2s, in particular UbcH5a (Figure 
20). This was evident through the appearance that the greatest amount of poly-
ubiquitination occurs in the presence of the E2 UbcH5a. The formation of E2-
ubiqutin complexes was observed during conjugation assays as is evident by 57 
kDa, 60 kDa, 70 kDa, and 75 kDa polypeptides that represent the UbcH10-Ub, 
UbcH6-Ub, UbcH3-Ub, and UbcH5-Ub complexes respectively. This was not 
surprising as ubiquitin is known to bind E2 prior to transfer of the ubiquitin 
moiety onto the target protein during the ubiquitin conjugation reaction (Figure 
9). 
 
4.6.2 Key components involved in SNAMA E3 ubiquitination   
 
Ubiquitin is capable of forming poly-ubiquitin chains of 2 to 3 molecules, 70 kDa 
and ~ 100 kDa in size respectively, in the presence of E1 and E2 and in the 
absence of the E3 (SNAMA) (Figure 21). The 75 kDa peptide in this sample 
represents the UbcH5a-Ub complex as described earlier. However, reaction 
mixtures in which E3 was present show far more prominent bands as well as the 
presence of additional polypeptides, particularly the bigger polypeptides greater 
than 170 kDa (Figure 22). This indicates unequivocally that SNAMA E3 is 
essential for ubiquitination and catalyses self-ubiquitination. 
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Figure 21. The dependence of SNAMA E3 activity on key ubiquitination factors. 
Ubiquitin conjugation assays using SNAMA E3 were performed in the absence of 
each of the key players involved in ubiquitination including E1, E2, ubiquitin, or 
zinc ions. Ubiquitination does not occur in the absence of ubiquitin, E1 or E2 
(lanes 3, 4 and 5 respectively). However, ubiquitination takes place in the absence 
of zinc ions (lane 2). Poly-ubiquitin chains of 2 to 3 molecules and the Ubc5a-Ub 
complex still form in the absence of the E3 (SNAMA) as is indicated by the three 
additional peptides of approximately 70 kDa, 75 kDa, and 100 kDa (lane 6). 
 
The dependence of SNAMA E3 activity on key factors involved in the 
ubiquitination process (E1, E2, ubiquitin, ZnCl2, ATP) was examined by 
performing conjugation assays in the absence of each of these factors (Figure 21 
and 22). E1, E2 and ubiquitin are crucial for ubiquitination to occur as is indicated 
by no ubiquitination occurring at all in their absence (Figure 21).  However, a 
polypeptide of approximately 110 kDa does arise in the absence of the ubiquitin 
activating enzyme (E1). This polypetide probably represents the interaction 
between E3 SNAMA (70 kDa) and the E2 (40 kDa) to form a E3-E2 complex and 
further confirms the specificity of SNAMA E3 for the E2 UbcH5a. ATP is 
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essential for ubiquitination as no ubiquitination occurs in its absence (Figure 22). 
Furthermore, the formation of the E3-E2 complex is dependent on ATP as no E3-
E2 complex formed in the absence of ATP. This is not surprising as ATP is 
required for the activation of ubiquitin by E1..  
  
 
Figure 22. The effect of ATP on SNAMA E3 activity. Ubiquitin conjugation 
assays using SNAMA E3 in the presence of ATP results in ubiquitination as is 
evident by the additional polypeptides present as a “smear” in the sample (lanes 1 
and 3). Reaction mixtures without ATP showed no sign of ubiquitination at all as 
there were no additional polypeptides when the sample was separated (lanes 1 and 
5). Ubiquitin and the E1 were present in all the reaction mixtures when testing for 
the dependence of SNAMA activity on ATP.   
 
Surprisingly, SNAMA E3 mediated ubiquitination is not dependent on zinc ions 
for its activity as polyubiquitination occurs in the absence of ZnCl2 (Figure 21). In 
fact, ubiquitination appears more prominent when zinc is absent than when it is 
present reaction mixture.  
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5. DISCUSSION 
 
Evidence suggests that SNAMA plays a role in Drosophila development and in 
apoptosis, probably as a suppressor of apoptosis or negative regulator of an 
activator of apoptosis  (Mather et al., 2005; Jones et al., 2006). Recently, SNAMA 
was characterized by Jones and his colleagues, who named the gene mini-me (mnm) 
(Jones et al., 2006). They identified SNAMA/mnm as a dominant modifier of 
hedgehog loss-of-function. Furthermore, they go on to show that SNAMA/mnm is 
required for normal cell proliferation and for cell survival anterior to the furrow of 
the Drosophila eye, but not posterior to it. Thus, their findings go hand-in-hand 
with our hypothesis that SNAMA/mnm is involved in cell proliferation as a 
negative regulator of apoptosis.   
 
Preliminary studies have shown that SNAMA probably interacts with Dmp53 and 
is involved in apoptosis via the Dmp53 pathway (Mather thesis, 2005). Further 
preliminary studies illustrated that the interaction between Dmp53 and SNAMA 
occurs through the DWNN domain within the DCM (Rakgotho, thesis, 2007). 
Groundwork has also shown that increased levels of SNAMA mRNA and protein 
probably result in decreased levels of Dmp53 and vice versa (Hull, personal 
communication). Thus, SNAMA appears to regulate apoptosis through the negative 
regulation of the pro-apoptotic protein, Dmp53. This is consistent with other 
members of the RbBP6 family of proteins, which are involved in tumorigenesis 
through the negative regulation of p53 and Rb (Li et al., 2007).    
 
Transcriptional regulation of SNAMA was examined through analysis of the core 
promoter elements surrounding the transcription start site of the gene (Ntwasa and 
Antunes, in preparation). This was achieved by 5´  RACE, which allowed for 
analysis of the 5´  region of the gene by ensuring the amplification of capped 
transcripts.  
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Further elucidation of the functional role of SNAMA was determined by 
confirming whether it exhibits ubiquitin ligase activity. SNAMA contains an 
ubiquitin-like DWNN domain followed closely by a RFL motif within its DCM at 
its N-terminus (Mather et al., 2005). The RING finger conformation is responsible 
for supplying RING finger E3s and U-box E4s with their activity, as they play an 
essential role in conjugation of ubiquitin to target proteins (Joazeiro and 
Weissman, 2000; Aravind and Koonin, 2000). The notion that the RFL motif 
would supply SNAMA with ubiquitin ligase activity was tested by ubiquitin 
conjugation assays using pure and active recombinant SNAMA as the E3. 
Furthermore, the dependence of SNAMA E3 activity on key components of the 
ubiquitination process was determined.    
 
5.1 A Single TATA-less Promoter Regulates Expression of 
SNAMA  
 
The transcription start site of SNAMA was initially predicted to be approximately 
2.2 kb from the translation start site, which would have given rise to mRNA of 
approximately 4.6 kb (Mather et al., 2005). Determination of the transcriptional 
start site by 5´  RACE implies that the SNAMA transcript would be approximately 
3.9 kb in size. This finding was supported by Jones and his colleagues who 
identified the expression of 3.9 kb transcript throughout development in 
Drosophila (Jones et al., 2006). Thus, the SNAMA transcript has a 5´  UTR of 81 
nucleotides, interrupted by a large first intron of 0.84 kb, and giving rise to an 
mRNA sequence of approximately 3.9 kb.  
 
Determining the transcription start site of a gene makes it possible to identify 
regulatory regions of that gene and ultimately the promoter region. We show that 
there is a single site of transcription initiation for the SNAMA gene (Figure 12; 
Appendix I). A sequence extending 1000 bases upstream and 70 bases 
downstream from the transcription start site was used to search for potential 
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transcription factor binding sites and core promoter elements (Ntwasa and 
Antunes, in preparation).  
 
No plausible TATA box was identified in the expected region 23-33 bp upstream 
of the transcription start site, however, it is known that less than 40% of 
Drosophila promoters do not contain a recognizable TATA box (Gershenzon et 
al., 2006). Furthermore, the sequence at the transcription start site (GCATC) 
matches the published initiator element (Inr) consensus sequence, which is 
present in approximately 65% of Drosophila promoters (Gershenzon et al., 2006). 
There is also a good sequence match (GTCG) with the downstream promoter 
element (DPE) consensus sequence, 32 residues downstream from the 
transcription start site (Appendix I).  
 
In order for transcription initiation to occur in Drosophila the general 
transcription factor TFIID must first bind the promoter, thereby creating a 
platform for the assembly of additional components of the initiation complex. 
TFIID requires one of three elements or combination of them in order for this to 
occur, namely the TATA box, Inr and the DPE. Thus, SNAMA has a TATA-less 
promoter region containing a combination of the core elements Inr-DPE that is 
needed for the binding of the transcription initiation factor TFIID. 
 
This work shows that SNAMA is regulated by a single TATA-less promoter that 
gives rise to a transcript of approximately 3.9 kb. However, an additional 
transcript of SNAMA, approximately 1.8 kb in size, has also been identified in 
Drosophila during devlopment (Jones et al., 2006). The size of this additional 
transcript seems to indicate the independent expression of the DWNN domain, 
much like its mammalian RbBP6 counterpart. However, further experimental 
evidence is needed in order to confirm this hypothesis.       
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5.2 SNAMA Exhibits Ubiquitin Ligase Activity  
 
The release of sequence data, particularly from a number of medically and 
biotechnologically important genomes such as that of Drosophila, is increasing in 
an exponential fashion. In light of this, elucidating the structure and function of 
proteins in these organisms is important. Determining whether the DCM of 
SNAMA portrayed ubiquitin ligase activity was extensive and complex. It 
involved a number of consecutive processes that ultimately led to a pure and 
active form of the SNAMA protein that could be used as the ubiquitin ligase in an 
ubiquitin conjugation assay.    
 
5.2.1 SNAMA has E3 activity capable of auto-ubiquitination  
 
The DCM of SNAMA exhibits ubiquitin ligase activity that is capabe of self-
ubiquitination (Figure 20). Auto-ubiquitination of SNAMA during the ubiquitin 
conjugation assays is most likely due to the ubiquitin-like DWNN domain within 
the DCM. This domain probably serves as the substrate for the covalent 
attachment of ubiquitin molecules by the RFL motif of SNAMA. This attachment 
most likely occurs at the conserved K29 residue and not the more common K48 
residue as this conserved lysine is absent in the DWNN domain. The choice of the 
lysine residue used to form the ubiquitin chain influences the fate of the 
ubiquitinated protein (Stone et al., 2005). The fate of K48 and K29 poly-
ubiquitinated proteins is degradation by the 26S proteasome (Pugh et al., 2006), 
whereas protein modification with a poly-ubiquitin K63 chain has been implicated 
in protein activation (Deng et al., 2000).  It is possible that SNAMA utilizes 
different lysine residues on ubiquitin for poly-ubiquitination in comparison to 
characteristic RING finger E3s. Further investigation is needed to determine the 
exact lysine residue that is used during ubiquitination.   
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5.2.2 SNAMA demonstrates optimal activity with UbcH5a  
 
The presence or absence of polypeptides in the gel at sizes greater than 100 kDa 
indicates whether poly-ubiquitination has occurred or not occurred respectively 
(Figure 20). Using this information it can be noted that SNAMA has ubiquitin 
ligase activity in the presence of a number of E2s that include UbcH2, UbcH3, 
UbcH5 and UbcH6. However, SNAMA has no activity in the presence of the E2s 
UbcH7 and UbcH10. Furthermore, it appears as though the activity of SNAMA is 
greatest when using the UbcH5a conjugating enzyme due to the greater intensity 
of the bands, thus confirming that SNAMA has greatest specificity for UbcH5a. 
RING finger ubiquitin ligases bind specifically to an E2 in addition to a target 
protein in order to promote ubiquitination of the target protein. SNAMA probably 
binds UbcH5a and forms an E3-E2 complex through contacts between a groove in 
the RING domain and the two loops in the E2 fold (Zhou and Howley, 1998). The 
function of SNAMA ubiquitin ligase activity is therefore dependent on its RING 
finger-like motif within the DCM that forms a RING finger structure.  
 
5.2.3 SNAMA is a classical RING fingerE3 
 
SNAMA mediated ubiquitination occurs in the presence and absence of zinc ions. 
Typical RING fingers are known for their dependence on divalent metal ions, 
such as zinc, in order to exhibit their ligase activity (Freemont, 1993) whilst U-
box E4s are capable of ubiquitination in the absence of divalent ions (Hatakeyama 
et al., 2001). The reason for this can be attributed to the way in which each ligase 
stabilizes its RING finger conformation, which is dependent on the sequence 
composition of their domains. Characteristic RING finger E3s rely on conserved 
cysteine and histidine residues, that co-ordinate two zinc ions to maintain their 
RING finger conformation (Borden, 2000; Saurin et al., 1996). In contrast, U-box 
E4s stabilize their RING finger fold through hydrogen bonds, salt-bridges and 
conserved hydrophobic residues within its consensus. 
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The fact that SNAMA has ubiquitin ligase activity in the absence of zinc ions 
seems to indicate that the RFL motif still forms a RING finger structure in the 
absence of zinc ions. It is easy to assume that SNAMA is a U-box E4 due to it 
having activity in the absence of zinc ions. However, closer investigation shows 
that the primary structure of the RFL motif resembles that of a RING finger 
domain and not a U-box domain. Multiple sequence alignments between the 
SNAMA RFL motif and the RFL motifs of other RbBP6 proteins show that they 
all have a consensus sequence like that of the “classical” RING finger domain 
(Figure 23). This is evident by the presence of highly conserved cysteine residues 
in the correct positions within their sequences. In contrast, the characteristic U-
box domain from Ufd2 showed no significant homology to either the SNAMA 
RFL motif or other RbBP6 family proteins. 
 
SNAMA can be defined as a RING finger-like protein that functions as a 
chracteristic RING finger E3 and not a U-box E4. There is no experimental 
evidence to demonstrate exactly how the RING finger conformation of the RFL 
motif is being stabilized. However, the RING finger fold is probably maintained 
by salt-bridges, hydrogen-bonds and disulphide bonds between cysteine residues, 
that form during refolding of denatured recombinant SNAMA into its native state. 
To assume that SNAMA is a U-box protein would be bold, especially with no 
experimental evidence of how the RING conformation is stabilized. Further 
research of the crystal structure of the DCM of SNAMA would confirm the 
characterization of SNAMA as a RING finger E3. 
 
This work represents the first evidence of a member of the RbBP6 family of 
proteins having ubiquitin ligase activity. It has been suggested on a number of 
occasions, by various groups, that RbBP6 proteins would exhibit ubiquitin ligase 
activity due to the presence of a RING finger-like motif in the DCM of these 
proteins. Li and his colleagues showed that the mouse RbBP6 protein (PACT) 
interacts with Hdm2 and enhances Hdm2-mediated ubiquitination and 
degradation of p53 as a result of an increase in p53-Hdm2 affinity (Li et al., 
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2007). However, no group has shown that a member of the RbBP6 protein family 
has ubiquitin ligase activity on its own until now, where it is shown that SNAMA 
is capable of ubiquitination. SNAMA is also one of very few proteins that 
contains a RFL motif capable of exhibiting ubiquitin ligase activity. Furthermore, 
SNAMA is the first protein to exhibit “classical” RING finger ligase activity in 
vitro, in the absence of zinc ions. 
 
 
Figure 23. Multiple alignment of RING finger motifs from the RbBP6 
superfamily. Orthologues of the SNAMA RFL motif were generated from the 
BlastP bioinformatic tool followed by alignment of the sequences using ClustalX. 
The conserved cysteine residues involved in the formation of the cross-brace 
structure of the RING finger are numbered at the top of the sequences. The 
conserved histidine in the fourth ligand has been substituted in all the RFL motifs 
of the RbBP6 family of protein. The classical U-box protein, Ufd2, was also 
included in the alignment.      
 
SNAMA is involved in regulatory pathways that affect apoptosis and cell 
proliferation. A number of preliminary studies also show a definite association 
between SNAMA and Dmp53, much like other members of the RbBP6 
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superfamily. Furthermore, SNAMA functions as a target-specific RING finger E3 
capable of ubiquitination. Ubiquitination is pivotal for the modification of 
proteins that are involved in a wide variety cellular process, thereby maintaining 
the homeostasis within the cell. Thus, SNAMA represents a desirable target for 
drug therapy and pharmaceutical intervention due to its high specificity and 
ubiquitination of target proteins that are involved in important cell signalling 
pathways, that include apoptosis.        
 
5.3 Conclusion 
 
• The SNAMA gene is regulated by a single TATA-less promoter that gives rise 
to a single characterized transcript of approximately 3.9 kb.  
 
• SNAMA is a characteristic RING finger ubiquitin ligase that it is capable of 
auto-ubiquitination, particularly in the presence of UbcH5a. 
 
• SNAMA is the first identified RING finger E3 that is capable of 
ubiquitination in the absence of zinc ions in vitro. 
 
• This work represents the first evidence of a member of the RbBP6 family of 
proteins having ubiquitin ligase activity and shows that SNAMA is one of few 
proteins to exhibit ubiquitin ligase activity having a RFL motif.  
 
• SNAMA is an important target for drug therapy and pharmaceutical 
intervention. 
 
5.4 Future Work 
 
The first objective would be to generate a pure and active recombinant Dmp53 
protein that could be used as a substrate during the ubiquitin conjugation reaction. 
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Dmp53 has already been shown to bind SNAMA in vivo and increased levels of 
SNAMA results in decreased levels of Dmp53 and vice versa. Therefore, 
determining whether SNAMA catalyzes the ubiquitination of Dmp53 would 
increase the understanding of programmed cell death in Drosophila through 
Dmp53. Furthermore, Dmp53 ubiquitination by SNAMA would confirm an 
interaction between the two proteins and the involvement of SNAMA in 
programmed cell death through Dmp53 regulation.  
 
The determination of the lysine residues utilized during auto-ubquitination of 
SNAMA and formation of poly-ubiquitin chains would be useful in providing 
insight into the fate of proteins that are ubquitinated by SNAMA. This could be 
determined by mutational analysis of lysine residues in the DWNN domain of 
SNAMA, or lysine residues in the ubiquitin molecules that are used during the 
ubiquitination process. Alternatively, the crystal structure of the auto-
ubiquitinated SNAMA would illustrate the lysine residues that are being utilized 
during ubiquitination. 
 
Examining the way in which the RING finger conformation of the RFL motif is 
stabilized could be another important investigation. This would support the fact 
that SNAMA functions as a RING finger E3 and not a U-box E4. This would 
most easily be achieved by examining the crystal structure of the DCM of 
SNAMA. However, it would be possible to examine how the RFL motif is 
stabilized through mutational analysis of important residues (such as the 
conserved cysteines) in the RFL of the DCM.    
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6. APPENDIX 
 
6.1 Appendix I 
The SNAMA Protein and cDNA Sequence (NCBI, Locus no. NM_138040) 
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KEY 
Blue:   Reverse primers used for 5´  RACE and sequencing  
Underlined:  DWNN Catalytic Module (DCM) of SNAMA 
Green:   DWNN domain 
Purple:   Zinc finger motif 
Red:   RING finger-like motif 
Red Block:  Transcriptional start site (T.S.S.) 
Inr & DPE:  Initiator and Downstream Promoter Element  
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6.2 Appendix II 
Chromosome Map of the 5´  RACE Products  
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6.3 Appendix III 
iFOLDTM Protein Refolding System Plate Layout 
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6.4 Appendix IV 
Secondary structure prediction for SNAMA DCM 
 
(A) Prediction of the DCM secondary structure using PSIPRED 
(B) The secondary structures of the domains within the DCM as mentioned in the 
literature. 
 114
6.5 Appendix V 
TA cloning vectors  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pGEM-T easy cloning vector map and MCS (Promega, A 1360) 
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pCR®4-TOPO® cloning vector and MCS  
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6.6 Appendix VI 
pET41(a) expression vector map and MCS (Novagen, 70556-3) 
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6.7 Appendix VII 
CD spectra of characteristic secondary structures 
 
Typical CD spectra for an α-helical protein (Kelly and Price, 2000) 
 
Basic CD spectra extrapolated from spectra from 16 proteins (Greenfield, 2004) 
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6.8 Appendix VIII 
The molecular weight markers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GeneRulerTM 100 bp DNA Ladder Plus  PageRulerTM Prestained Protein 
Ladder 
(Fermentas, SM0321)    (Fermentas, SM0671) 
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